US20050171183A1 - Indole-type inhibitors of p38 kinase - Google Patents
Indole-type inhibitors of p38 kinase Download PDFInfo
- Publication number
- US20050171183A1 US20050171183A1 US11/098,905 US9890505A US2005171183A1 US 20050171183 A1 US20050171183 A1 US 20050171183A1 US 9890505 A US9890505 A US 9890505A US 2005171183 A1 US2005171183 A1 US 2005171183A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- compound
- aryl
- alkenyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title description 20
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 title description 20
- 239000003112 inhibitor Substances 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 113
- 125000003118 aryl group Chemical group 0.000 claims abstract description 65
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 17
- 125000001424 substituent group Chemical group 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 125000003342 alkenyl group Chemical group 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- -1 NH-aroyl Chemical group 0.000 claims description 22
- 125000000304 alkynyl group Chemical group 0.000 claims description 21
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- 125000002252 acyl group Chemical group 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 19
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 claims description 15
- 125000004429 atom Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000003435 aroyl group Chemical group 0.000 claims description 13
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- 150000002923 oximes Chemical class 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 4
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 150000003536 tetrazoles Chemical class 0.000 claims description 3
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000006362 methylene amino carbonyl group Chemical group [H]N(C([*:2])=O)C([H])([H])[*:1] 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 9
- 102000020233 phosphotransferase Human genes 0.000 abstract description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 80
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 38
- 235000019439 ethyl acetate Nutrition 0.000 description 31
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 239000002904 solvent Substances 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 239000012267 brine Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 12
- 0 cc Chemical compound cc 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 125000001183 hydrocarbyl group Chemical group 0.000 description 10
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 10
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 8
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical group CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 239000007868 Raney catalyst Substances 0.000 description 6
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 6
- 229910000564 Raney nickel Inorganic materials 0.000 description 6
- 206010040070 Septic Shock Diseases 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 150000002475 indoles Chemical group 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 150000004885 piperazines Chemical class 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical group O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- DSHBGNPOIBSIOQ-UHFFFAOYSA-N methyl 4-amino-2-chlorobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1Cl DSHBGNPOIBSIOQ-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- UPRIOUMJBBRMDT-UHFFFAOYSA-N 2-[6-chloro-5-[1-[(4-fluorophenyl)methyl]-1,7-diazaspiro[4.4]nonane-7-carbonyl]-1-methylindol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound C1=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=CC(Cl)=C1C(=O)N(C1)CCC21CCCN2CC1=CC=C(F)C=C1 UPRIOUMJBBRMDT-UHFFFAOYSA-N 0.000 description 3
- CXDPVBDDAGYWDZ-UHFFFAOYSA-N 2-n-[(4-fluorophenyl)methyl]-2-n-methylcyclohexane-1,2-diamine Chemical compound C1CCCC(N)C1N(C)CC1=CC=C(F)C=C1 CXDPVBDDAGYWDZ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000009525 Myocarditis Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- SUAKIVNGQVUKJA-GFCCVEGCSA-N [(3r)-1-benzylpyrrolidin-3-yl]methanamine Chemical compound C1[C@@H](CN)CCN1CC1=CC=CC=C1 SUAKIVNGQVUKJA-GFCCVEGCSA-N 0.000 description 3
- 150000005415 aminobenzoic acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006353 environmental stress Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 150000003053 piperidines Chemical class 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- SZJIQLSCDIEJFC-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-methylmethanamine Chemical compound CNCC1=CC=C(F)C=C1 SZJIQLSCDIEJFC-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- SJQFSWQKJXXJMR-UHFFFAOYSA-N 2-[5-[1-[(4-fluorophenyl)methyl]piperidine-4-carbonyl]-6-methoxy-1-methylindol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound COC1=CC=2N(C)C=C(C(=O)C(=O)N(C)C)C=2C=C1C(=O)C(CC1)CCN1CC1=CC=C(F)C=C1 SJQFSWQKJXXJMR-UHFFFAOYSA-N 0.000 description 2
- IUGUZAFCSVZTBN-UHFFFAOYSA-N 2-[6-methoxy-1-methyl-5-(piperidine-4-carbonyl)indol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound COC1=CC=2N(C)C=C(C(=O)C(=O)N(C)C)C=2C=C1C(=O)C1CCNCC1 IUGUZAFCSVZTBN-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- CNTICKSUVMYZBZ-UHFFFAOYSA-N C1CC12CC2.C1CC2CCCC2C1.C1CCCC1.C1CCCCC1.CC.CC.CC.CC.CC.CC.CC.CC Chemical compound C1CC12CC2.C1CC2CCCC2C1.C1CCCC1.C1CCCCC1.CC.CC.CC.CC.CC.CC.CC.CC CNTICKSUVMYZBZ-UHFFFAOYSA-N 0.000 description 2
- XSJJCKWFLFUIKO-UHFFFAOYSA-N CC.CC1CCN(C)CC1 Chemical compound CC.CC1CCN(C)CC1 XSJJCKWFLFUIKO-UHFFFAOYSA-N 0.000 description 2
- KGRDVCXTCVANFD-UHFFFAOYSA-N CC.CCCC[Ar].c1c-c2ccccc2C1 Chemical compound CC.CCCC[Ar].c1c-c2ccccc2C1 KGRDVCXTCVANFD-UHFFFAOYSA-N 0.000 description 2
- OKBGIRUZOBMRGS-UHFFFAOYSA-N CN(C)C(=O)C(=O)C1=CNC2=CC(Cl)=C(C(=O)NC3CCCCC3N(C)CC3=CC=C(F)C=C3)C=C21 Chemical compound CN(C)C(=O)C(=O)C1=CNC2=CC(Cl)=C(C(=O)NC3CCCCC3N(C)CC3=CC=C(F)C=C3)C=C21 OKBGIRUZOBMRGS-UHFFFAOYSA-N 0.000 description 2
- ZJGDNFNPGOSEBD-UHFFFAOYSA-N CNCC1=CC=C(F)C=C1.CO.O=CC1=CC=C(F)C=C1 Chemical compound CNCC1=CC=C(F)C=C1.CO.O=CC1=CC=C(F)C=C1 ZJGDNFNPGOSEBD-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 206010063094 Cerebral malaria Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 2
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 2
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 108010068306 MAP Kinase Kinase 6 Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000010001 Silicosis Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 208000019664 bone resorption disease Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- PWBJWDKDPAPGED-UHFFFAOYSA-N n'-chlorobutanediamide Chemical compound NC(=O)CCC(=O)NCl PWBJWDKDPAPGED-UHFFFAOYSA-N 0.000 description 2
- QDMIBGPCANIXOE-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-n-methyl-2-nitrocyclohexan-1-amine Chemical compound C1CCCC([N+]([O-])=O)C1N(C)CC1=CC=C(F)C=C1 QDMIBGPCANIXOE-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000013389 whole blood assay Methods 0.000 description 2
- NCNSBFDGXBKAKB-UHFFFAOYSA-N (methylsulfanyl)acetaldehyde Chemical compound CSCC=O NCNSBFDGXBKAKB-UHFFFAOYSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- IZXWCDITFDNEBY-UHFFFAOYSA-N 1-(chloromethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCl)C=C1 IZXWCDITFDNEBY-UHFFFAOYSA-N 0.000 description 1
- JDDQZZXVRPTJKZ-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-1,7-diazaspiro[4.4]nonane Chemical compound C1=CC(F)=CC=C1CN1C2(CNCC2)CCC1 JDDQZZXVRPTJKZ-UHFFFAOYSA-N 0.000 description 1
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical compound CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 description 1
- IXPJEZDGDWSEIM-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(6-methoxy-1-methylindole-5-carbonyl)piperidin-1-yl]ethanone Chemical compound COC1=CC=2N(C)C=CC=2C=C1C(=O)C1CCN(C(=O)C(F)(F)F)CC1 IXPJEZDGDWSEIM-UHFFFAOYSA-N 0.000 description 1
- RBXJFAVOYNCVDO-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(6-methoxy-1h-indole-5-carbonyl)piperidin-1-yl]ethanone Chemical compound COC1=CC=2NC=CC=2C=C1C(=O)C1CCN(C(=O)C(F)(F)F)CC1 RBXJFAVOYNCVDO-UHFFFAOYSA-N 0.000 description 1
- XQIKXPXSWYNRSF-UHFFFAOYSA-N 2-(4-benzylpiperidin-1-yl)-1h-indole-5-carboxamide Chemical compound C=1C2=CC(C(=O)N)=CC=C2NC=1N(CC1)CCC1CC1=CC=CC=C1 XQIKXPXSWYNRSF-UHFFFAOYSA-N 0.000 description 1
- LKACNQYMNIUFDG-UHFFFAOYSA-N 2-[6-chloro-5-[2-[(4-fluorophenyl)methyl]-3a,6a-dimethyl-1,3,4,6-tetrahydropyrrolo[3,4-c]pyrrole-5-carbonyl]-1-methylindol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound C1=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=CC(Cl)=C1C(=O)N(CC1(C)C2)CC1(C)CN2CC1=CC=C(F)C=C1 LKACNQYMNIUFDG-UHFFFAOYSA-N 0.000 description 1
- ZMKWKFVNSCGYEL-UHFFFAOYSA-N 2-[6-methoxy-1-methyl-5-[1-(2,2,2-trifluoroacetyl)piperidine-4-carbonyl]indol-3-yl]-n,n-dimethyl-2-oxoacetamide Chemical compound COC1=CC=2N(C)C=C(C(=O)C(=O)N(C)C)C=2C=C1C(=O)C1CCN(C(=O)C(F)(F)F)CC1 ZMKWKFVNSCGYEL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- XJFZOSUFGSANIF-UHFFFAOYSA-N 3-chloro-2-(chloromethyl)prop-1-ene Chemical compound ClCC(=C)CCl XJFZOSUFGSANIF-UHFFFAOYSA-N 0.000 description 1
- BIFDJPLEABLCKG-UHFFFAOYSA-N 4-benzylpiperidin-2-one Chemical compound C1CNC(=O)CC1CC1=CC=CC=C1 BIFDJPLEABLCKG-UHFFFAOYSA-N 0.000 description 1
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical class C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- LJUAQFUHMMWPBX-UHFFFAOYSA-N 6-methoxy-2-methyl-1h-indole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(OC)=CC2=C1C=C(C)N2 LJUAQFUHMMWPBX-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- TXDKDXTYCXFYDB-UHFFFAOYSA-N C.C.C.C.C1CNCCN1.CC.CC.CC.[Ar]CN1CCNCC1.[Ar]CN1CCNCC1 Chemical compound C.C.C.C.C1CNCCN1.CC.CC.CC.[Ar]CN1CCNCC1.[Ar]CN1CCNCC1 TXDKDXTYCXFYDB-UHFFFAOYSA-N 0.000 description 1
- RFWVIQZLVJGHOF-UHFFFAOYSA-N C.C.C.CC.CC.CC.CC([Ar])([Y])C1CCNCC1.C[IH]C(=O)C1CCN(C(=O)C(F)(F)F)CC1.O=C([Ar])C1CCN(C(=O)C(F)(F)F)CC1.[Ar] Chemical compound C.C.C.CC.CC.CC.CC([Ar])([Y])C1CCNCC1.C[IH]C(=O)C1CCN(C(=O)C(F)(F)F)CC1.O=C([Ar])C1CCN(C(=O)C(F)(F)F)CC1.[Ar] RFWVIQZLVJGHOF-UHFFFAOYSA-N 0.000 description 1
- BLWZPBIQPCHNTK-UHFFFAOYSA-K C.CC.CC.CCC=O.I[V](I)I.O=C1CCN(CC2=CC=CC=C2)CC1.[Ar]CC1CCNCC1 Chemical compound C.CC.CC.CCC=O.I[V](I)I.O=C1CCN(CC2=CC=CC=C2)CC1.[Ar]CC1CCNCC1 BLWZPBIQPCHNTK-UHFFFAOYSA-K 0.000 description 1
- ZVNWNDGJHAIWEK-UHFFFAOYSA-N C1CCNCC1.CC(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1CCC(CC3=CC=C([Y])C=C3)CC1)C(C)=C2.CC1=CC2=C(C=C1C(=O)N1CCC(CC3=CC=C([Y])C=C3)CC1)C(C(=O)C(=O)Cl)=CN2.CC1=CC2=C(C=C1C(=O)N1CCC(CC3=CC=C([Y])C=C3)CC1)C(C(=O)C(=O)O)=CN2.CC1=CC2=C(C=CN2)C=C1C(=O)N1CCC(CC2=CC=C([Y])C=C2)CC1.CCCN.CN1CCNCC1.ClCCl Chemical compound C1CCNCC1.CC(=O)C(=O)C1=CNC2=C1C=C(C(=O)N1CCC(CC3=CC=C([Y])C=C3)CC1)C(C)=C2.CC1=CC2=C(C=C1C(=O)N1CCC(CC3=CC=C([Y])C=C3)CC1)C(C(=O)C(=O)Cl)=CN2.CC1=CC2=C(C=C1C(=O)N1CCC(CC3=CC=C([Y])C=C3)CC1)C(C(=O)C(=O)O)=CN2.CC1=CC2=C(C=CN2)C=C1C(=O)N1CCC(CC2=CC=C([Y])C=C2)CC1.CCCN.CN1CCNCC1.ClCCl ZVNWNDGJHAIWEK-UHFFFAOYSA-N 0.000 description 1
- FANGTSVWNMWHPC-UHFFFAOYSA-N C1CCOC1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C(C#C[Si](C)(C)C)C(NC(C)=O)=C1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C=CNC2=C1 Chemical compound C1CCOC1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C(C#C[Si](C)(C)C)C(NC(C)=O)=C1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C=CNC2=C1 FANGTSVWNMWHPC-UHFFFAOYSA-N 0.000 description 1
- CPGZEXJIPHIMHO-CAXSXHRYSA-N C=C(ON1N=NC2=CC=CN=C21)N(C)C.CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)NC[C@@H]3CCN(CC4=CC=CC=C4)C3)C=C12.CN1C=CC2=CC(C(=O)NC[C@@H]3CCN(CC4=CC=CC=C4)C3)=C(Cl)C=C21.CN1C=CC2=CC(C(=O)O)=C(Cl)C=C21.CNC.NC[C@@H]1CCN(CC2=CC=CC=C2)C1 Chemical compound C=C(ON1N=NC2=CC=CN=C21)N(C)C.CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)NC[C@@H]3CCN(CC4=CC=CC=C4)C3)C=C12.CN1C=CC2=CC(C(=O)NC[C@@H]3CCN(CC4=CC=CC=C4)C3)=C(Cl)C=C21.CN1C=CC2=CC(C(=O)O)=C(Cl)C=C21.CNC.NC[C@@H]1CCN(CC2=CC=CC=C2)C1 CPGZEXJIPHIMHO-CAXSXHRYSA-N 0.000 description 1
- AFGGAPRVSSHHIG-UHFFFAOYSA-M C=C1CN(S(=O)(=O)C2=CC=C(C)C=C2)CC(=C)CN(S(=O)(=O)C2=CC=C(C)C=C2)C1.CC1=CC=C(S(N)(=O)=O)C=C1.O=C(CCl)CCl.O=COO[K].[KH] Chemical compound C=C1CN(S(=O)(=O)C2=CC=C(C)C=C2)CC(=C)CN(S(=O)(=O)C2=CC=C(C)C=C2)C1.CC1=CC=C(S(N)(=O)=O)C=C1.O=C(CCl)CCl.O=COO[K].[KH] AFGGAPRVSSHHIG-UHFFFAOYSA-M 0.000 description 1
- LTVIPFRLWRVJCM-ZMCUFYFBSA-N C=C1CN(S(=O)(=O)C2=CC=C(C)C=C2)CC(=C)CN(S(=O)(=O)C2=CC=C(C)C=C2)C1.C[C@]12CNC[C@@]1(C)CNC2.[AlH3].[LiH] Chemical compound C=C1CN(S(=O)(=O)C2=CC=C(C)C=C2)CC(=C)CN(S(=O)(=O)C2=CC=C(C)C=C2)C1.C[C@]12CNC[C@@]1(C)CNC2.[AlH3].[LiH] LTVIPFRLWRVJCM-ZMCUFYFBSA-N 0.000 description 1
- INUFNUMFRSCNIH-UHFFFAOYSA-N CC.CC1=C(C)NN=N1 Chemical compound CC.CC1=C(C)NN=N1 INUFNUMFRSCNIH-UHFFFAOYSA-N 0.000 description 1
- IKMVLNQGXGJCJQ-UHFFFAOYSA-N CC.CC1=NC=CN1 Chemical compound CC.CC1=NC=CN1 IKMVLNQGXGJCJQ-UHFFFAOYSA-N 0.000 description 1
- NMPRJEMPNIQBHV-UHFFFAOYSA-N CC.CC1=NN=NN1 Chemical compound CC.CC1=NN=NN1 NMPRJEMPNIQBHV-UHFFFAOYSA-N 0.000 description 1
- PXHODFDOEPBCEX-UHFFFAOYSA-N CC.CC1=NNC(C)=N1 Chemical compound CC.CC1=NNC(C)=N1 PXHODFDOEPBCEX-UHFFFAOYSA-N 0.000 description 1
- WMYCPJKLBJLZKI-UHFFFAOYSA-N CC1=CC2=CC(C(=O)O)=C(Cl)C=C2N1.COC(=O)C1=C(Cl)C=C(N)C=C1.COC(=O)C1=C(Cl)C=C(NC(C)C(OC)OC)C=C1.COC(=O)C1=C(Cl)C=C2NC(C)=CC2=C1.COC(=O)C1=CC=C2NC(C)=CC2=C1Cl.COC(OC)C(C)=O Chemical compound CC1=CC2=CC(C(=O)O)=C(Cl)C=C2N1.COC(=O)C1=C(Cl)C=C(N)C=C1.COC(=O)C1=C(Cl)C=C(NC(C)C(OC)OC)C=C1.COC(=O)C1=C(Cl)C=C2NC(C)=CC2=C1.COC(=O)C1=CC=C2NC(C)=CC2=C1Cl.COC(OC)C(C)=O WMYCPJKLBJLZKI-UHFFFAOYSA-N 0.000 description 1
- MPKMWBLASUJEFU-GUQANJBTSA-N CC1CCCCC1C.CC1CCN(C)CC1.CCN1CCC(C)C1.CCN1CCC(C)C1.CN1C[C@]2(C)CN(C)C[C@]2(C)C1 Chemical compound CC1CCCCC1C.CC1CCN(C)CC1.CCN1CCC(C)C1.CCN1CCC(C)C1.CN1C[C@]2(C)CN(C)C[C@]2(C)C1 MPKMWBLASUJEFU-GUQANJBTSA-N 0.000 description 1
- DDDVSPPZMYYQIR-UHFFFAOYSA-N CCC[Ar] Chemical compound CCC[Ar] DDDVSPPZMYYQIR-UHFFFAOYSA-N 0.000 description 1
- DBAUFYVBNYPHAH-UHFFFAOYSA-N CCO.COC1=C(C(=O)C2CCN(CC3=CC=C(F)C=C3)CC2)C=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=C1.COC1=C(C(=O)C2CCNCC2)C=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=C1 Chemical compound CCO.COC1=C(C(=O)C2CCN(CC3=CC=C(F)C=C3)CC2)C=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=C1.COC1=C(C(=O)C2CCNCC2)C=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=C1 DBAUFYVBNYPHAH-UHFFFAOYSA-N 0.000 description 1
- HUPQULXMEVBVRS-GMQYRYKESA-N CCO.C[C@@]12CNC[C@]1(C)CN(CC1=CC=C(F)C=C1)C2.C[C@]12CNC[C@@]1(C)CNC2.FC1=CC=C(CCl)C=C1 Chemical compound CCO.C[C@@]12CNC[C@]1(C)CN(CC1=CC=C(F)C=C1)C2.C[C@]12CNC[C@@]1(C)CNC2.FC1=CC=C(CCl)C=C1 HUPQULXMEVBVRS-GMQYRYKESA-N 0.000 description 1
- VDBZIMJMFYAXNY-UHFFFAOYSA-N CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)N3CCC4(CCCN4CC4=CC=C(F)C=C4)C3)C=C12.FC1=CC=C(CN2CCCC23CCNC3)C=C1 Chemical compound CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)N3CCC4(CCCN4CC4=CC=C(F)C=C4)C3)C=C12.FC1=CC=C(CN2CCCC23CCNC3)C=C1 VDBZIMJMFYAXNY-UHFFFAOYSA-N 0.000 description 1
- LKACNQYMNIUFDG-ISILISOKSA-N CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)N3C[C@]4(C)CN(CC5=CC=C(F)C=C5)C[C@]4(C)C3)C=C12 Chemical compound CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)N3C[C@]4(C)CN(CC5=CC=C(F)C=C5)C[C@]4(C)C3)C=C12 LKACNQYMNIUFDG-ISILISOKSA-N 0.000 description 1
- HRTDVGLJORSBFD-PZCMHQFRSA-N CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)N3C[C@]4(C)CN(CC5=CC=C(F)C=C5)C[C@]4(C)C3)C=C12.CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)NCC3CCN(CC4=CC=CC=C4)C3)C=C12.CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)NCC3CCN(CC4=CC=CC=C4)C3)C=C12.CN(C)C(=O)C(=O)C1=CNC2=CC(Cl)=C(C(=O)NC3CCCCC3N(C)CC3=CC=C(F)C=C3)C=C21 Chemical compound CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)N3C[C@]4(C)CN(CC5=CC=C(F)C=C5)C[C@]4(C)C3)C=C12.CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)NCC3CCN(CC4=CC=CC=C4)C3)C=C12.CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)NCC3CCN(CC4=CC=CC=C4)C3)C=C12.CN(C)C(=O)C(=O)C1=CNC2=CC(Cl)=C(C(=O)NC3CCCCC3N(C)CC3=CC=C(F)C=C3)C=C21 HRTDVGLJORSBFD-PZCMHQFRSA-N 0.000 description 1
- YCJQSTHNKATMCB-PSWIPPEHSA-N CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)N3C[C@]4(C)CN(CC5=CC=C(F)C=C5)C[C@]4(C)C3)C=C12.CN1C=CC2=CC(C(=O)N3C[C@]4(C)CN(CC5=CC=C(F)C=C5)C[C@]4(C)C3)=C(Cl)C=C21.ClCCl Chemical compound CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)N3C[C@]4(C)CN(CC5=CC=C(F)C=C5)C[C@]4(C)C3)C=C12.CN1C=CC2=CC(C(=O)N3C[C@]4(C)CN(CC5=CC=C(F)C=C5)C[C@]4(C)C3)=C(Cl)C=C21.ClCCl YCJQSTHNKATMCB-PSWIPPEHSA-N 0.000 description 1
- OYRKPEKWBBPBNW-UHFFFAOYSA-N CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)NCC3CCN(CC4=CC=CC=C4)C3)C=C12 Chemical compound CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)NCC3CCN(CC4=CC=CC=C4)C3)C=C12 OYRKPEKWBBPBNW-UHFFFAOYSA-N 0.000 description 1
- OYRKPEKWBBPBNW-SFHVURJKSA-N CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)NC[C@@H]3CCN(CC4=CC=CC=C4)C3)C=C12 Chemical compound CN(C)C(=O)C(=O)C1=CN(C)C2=CC(Cl)=C(C(=O)NC[C@@H]3CCN(CC4=CC=CC=C4)C3)C=C12 OYRKPEKWBBPBNW-SFHVURJKSA-N 0.000 description 1
- HYDYFLGEJIOASZ-MGWQCHBHSA-N CN(CC1=CC=C(F)C=C1)[C@@H]1CCCC[C@H]1N.CN(CC1=CC=C(F)C=C1)[C@@H]1CCCC[C@H]1[N+](=O)[O-].[Ni][RaH] Chemical compound CN(CC1=CC=C(F)C=C1)[C@@H]1CCCC[C@H]1N.CN(CC1=CC=C(F)C=C1)[C@@H]1CCCC[C@H]1[N+](=O)[O-].[Ni][RaH] HYDYFLGEJIOASZ-MGWQCHBHSA-N 0.000 description 1
- HXOXCXTWFBDBHG-NCTRVEHFSA-N CN(CC1=CC=C(F)C=C1)[C@@H]1CCCC[C@H]1N.COC1=C(C(=O)N[C@@H]2CCCC[C@H]2N(C)CC2=CC=C(F)C=C2)C=C2C(=C1)NC=C2C(=O)C(=O)N(C)C Chemical compound CN(CC1=CC=C(F)C=C1)[C@@H]1CCCC[C@H]1N.COC1=C(C(=O)N[C@@H]2CCCC[C@H]2N(C)CC2=CC=C(F)C=C2)C=C2C(=C1)NC=C2C(=O)C(=O)N(C)C HXOXCXTWFBDBHG-NCTRVEHFSA-N 0.000 description 1
- VZBLKGIPFMHNIK-IDHVVMMVSA-N CN(CC1=CC=C(F)C=C1)[C@@H]1CCCC[C@H]1[N+](=O)[O-].CNCC1=CC=C(F)C=C1.ClCCl.O=[N+]([O-])C1=CCCCC1 Chemical compound CN(CC1=CC=C(F)C=C1)[C@@H]1CCCC[C@H]1[N+](=O)[O-].CNCC1=CC=C(F)C=C1.ClCCl.O=[N+]([O-])C1=CCCCC1 VZBLKGIPFMHNIK-IDHVVMMVSA-N 0.000 description 1
- QTTQXGIXDVZZPI-QNBDYDFLSA-N CN1C=CC2=CC(C(=O)N3C[C@]4(C)CN(CC5=CC=C(F)C=C5)C[C@]4(C)C3)=C(Cl)C=C21.CN1C=CC2=CC(C(=O)O)=C(Cl)C=C21.C[C@@]12CNC[C@]1(C)CN(CC1=CC=C(F)C=C1)C2 Chemical compound CN1C=CC2=CC(C(=O)N3C[C@]4(C)CN(CC5=CC=C(F)C=C5)C[C@]4(C)C3)=C(Cl)C=C21.CN1C=CC2=CC(C(=O)O)=C(Cl)C=C21.C[C@@]12CNC[C@]1(C)CN(CC1=CC=C(F)C=C1)C2 QTTQXGIXDVZZPI-QNBDYDFLSA-N 0.000 description 1
- LJTQORKHMRFKHE-UHFFFAOYSA-N COC(=O)C1(CC#N)CCCN1C(=O)C1=CC=C(F)C=C1.COC(=O)C1CCCN1C(=O)C1=CC=C(F)C=C1.N#CCCl Chemical compound COC(=O)C1(CC#N)CCCN1C(=O)C1=CC=C(F)C=C1.COC(=O)C1CCCN1C(=O)C1=CC=C(F)C=C1.N#CCCl LJTQORKHMRFKHE-UHFFFAOYSA-N 0.000 description 1
- HXXYPXWRICTIOT-UHFFFAOYSA-N COC(=O)C1(CC#N)CCCN1C(=O)C1=CC=C(F)C=C1.C[Ni].O=C(C1=CC=C(F)C=C1)N1CCCC12CCNC2=O Chemical compound COC(=O)C1(CC#N)CCCN1C(=O)C1=CC=C(F)C=C1.C[Ni].O=C(C1=CC=C(F)C=C1)N1CCCC12CCNC2=O HXXYPXWRICTIOT-UHFFFAOYSA-N 0.000 description 1
- XGDFXNJCRPHKAZ-UHFFFAOYSA-N COC(=O)C1=C(Cl)C=C(N)C=C1.COC(=O)C1=C(Cl)C=C2NC=C(SC)C2=C1.COC(=O)C1=C(Cl)C=C2NC=CC2=C1.O=C(O)C1=C(Cl)C=C2NC=CC2=C1 Chemical compound COC(=O)C1=C(Cl)C=C(N)C=C1.COC(=O)C1=C(Cl)C=C2NC=C(SC)C2=C1.COC(=O)C1=C(Cl)C=C2NC=CC2=C1.O=C(O)C1=C(Cl)C=C2NC=CC2=C1 XGDFXNJCRPHKAZ-UHFFFAOYSA-N 0.000 description 1
- TXKXDCJOUYQMSR-UHFFFAOYSA-N COC(=O)C1=C(OC)C=C(N(C)CC(OC)OC)C=C1.COC(=O)C1=C(OC)C=C(N)C=C1.COC(=O)C1=C(OC)C=C(NCC(OC)OC)C=C1.COC(=O)C1=C(OC)C=C2C(=C1)C=CN2C.COC(C=O)OC Chemical compound COC(=O)C1=C(OC)C=C(N(C)CC(OC)OC)C=C1.COC(=O)C1=C(OC)C=C(N)C=C1.COC(=O)C1=C(OC)C=C(NCC(OC)OC)C=C1.COC(=O)C1=C(OC)C=C2C(=C1)C=CN2C.COC(C=O)OC TXKXDCJOUYQMSR-UHFFFAOYSA-N 0.000 description 1
- VVBLYHUBCWPXJA-UHFFFAOYSA-N COC(=O)C1CCCN1.COC(=O)C1CCCN1C(=O)C1=CC=C(F)C=C1.O=C(Cl)C1=CC=C(F)C=C1 Chemical compound COC(=O)C1CCCN1.COC(=O)C1CCCN1C(=O)C1=CC=C(F)C=C1.O=C(Cl)C1=CC=C(F)C=C1 VVBLYHUBCWPXJA-UHFFFAOYSA-N 0.000 description 1
- QVPGJZSAXQQSQB-UHFFFAOYSA-N COC(C(CCC1)N1C(c(cc1)ccc1F)=O)=O Chemical compound COC(C(CCC1)N1C(c(cc1)ccc1F)=O)=O QVPGJZSAXQQSQB-UHFFFAOYSA-N 0.000 description 1
- BLWYXBNNBYXPPL-UHFFFAOYSA-N COC(C1NCCC1)=O Chemical compound COC(C1NCCC1)=O BLWYXBNNBYXPPL-UHFFFAOYSA-N 0.000 description 1
- PLXWKPNTJHRHKY-UHFFFAOYSA-N COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C(C#C[Si](C)(C)C)C(NC(C)=O)=C1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C(I)C(NC(C)=O)=C1 Chemical compound COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C(C#C[Si](C)(C)C)C(NC(C)=O)=C1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C(I)C(NC(C)=O)=C1 PLXWKPNTJHRHKY-UHFFFAOYSA-N 0.000 description 1
- YRMWDKYGYORBBT-UHFFFAOYSA-N COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C(I)C(NC(C)=O)=C1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=CC(NC(C)=O)=C1 Chemical compound COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C(I)C(NC(C)=O)=C1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=CC(NC(C)=O)=C1 YRMWDKYGYORBBT-UHFFFAOYSA-N 0.000 description 1
- SQWYRTWQICAAQT-UHFFFAOYSA-N COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=C1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C=CN(C)C2=C1 Chemical compound COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=C1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C=CN(C)C2=C1 SQWYRTWQICAAQT-UHFFFAOYSA-N 0.000 description 1
- GKYQDOLRYGJQKY-UHFFFAOYSA-M COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=C1.COC1=C(C(=O)C2CCNCC2)C=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=C1.O=COO[K].[KH] Chemical compound COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=C1.COC1=C(C(=O)C2CCNCC2)C=C2C(C(=O)C(=O)N(C)C)=CN(C)C2=C1.O=COO[K].[KH] GKYQDOLRYGJQKY-UHFFFAOYSA-M 0.000 description 1
- MHLYSKSNDLADET-UHFFFAOYSA-N COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C=CN(C)C2=C1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C=CNC2=C1 Chemical compound COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C=CN(C)C2=C1.COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=C2C=CNC2=C1 MHLYSKSNDLADET-UHFFFAOYSA-N 0.000 description 1
- AITINZYTLAULRT-UHFFFAOYSA-N COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=CC(NC(C)=O)=C1.COC1=CC=CC(NC(C)=O)=C1.O=C(O)C1CCN(C(=O)C(F)(F)F)CC1 Chemical compound COC1=C(C(=O)C2CCN(C(=O)C(F)(F)F)CC2)C=CC(NC(C)=O)=C1.COC1=CC=CC(NC(C)=O)=C1.O=C(O)C1CCN(C(=O)C(F)(F)F)CC1 AITINZYTLAULRT-UHFFFAOYSA-N 0.000 description 1
- OLOVKRBRJJURKD-UHFFFAOYSA-N COC1=C(C(=O)C2CCN(CC3=CC=C(F)C=C3)CC2)C=C2C(=C1)NC=C2C(=O)C(=O)N(C)C Chemical compound COC1=C(C(=O)C2CCN(CC3=CC=C(F)C=C3)CC2)C=C2C(=C1)NC=C2C(=O)C(=O)N(C)C OLOVKRBRJJURKD-UHFFFAOYSA-N 0.000 description 1
- SZYMWQNLQFJJFV-UHFFFAOYSA-N COC1=CC=CC(N)=C1.COC1=CC=CC(NC(C)=O)=C1 Chemical compound COC1=CC=CC(N)=C1.COC1=CC=CC(NC(C)=O)=C1 SZYMWQNLQFJJFV-UHFFFAOYSA-N 0.000 description 1
- YZSZJTQUQFLSDU-ZCFIWIBFSA-N C[C@H](CC1)CN1[IH]C Chemical compound C[C@H](CC1)CN1[IH]C YZSZJTQUQFLSDU-ZCFIWIBFSA-N 0.000 description 1
- RGUQREOIIJLRSV-YFKPBYRVSA-N C[IH]N(CC1)C[C@H]1I Chemical compound C[IH]N(CC1)C[C@H]1I RGUQREOIIJLRSV-YFKPBYRVSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PAIVQFLUQIJTSR-UHFFFAOYSA-N FC1=CC=C(CN2CCCC23CCNC3)C=C1.O=C(C1=CC=C(F)C=C1)N1CCCC12CCNC2=O.[AlH3].[LiH] Chemical compound FC1=CC=C(CN2CCCC23CCNC3)C=C1.O=C(C1=CC=C(F)C=C1)N1CCCC12CCNC2=O.[AlH3].[LiH] PAIVQFLUQIJTSR-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- LTBRACVJRXLQHC-UHFFFAOYSA-N OP(=O)OCC1=CC=CC=C1 Chemical class OP(=O)OCC1=CC=CC=C1 LTBRACVJRXLQHC-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- SUAKIVNGQVUKJA-LBPRGKRZSA-N [(3s)-1-benzylpyrrolidin-3-yl]methanamine Chemical compound C1[C@H](CN)CCN1CC1=CC=CC=C1 SUAKIVNGQVUKJA-LBPRGKRZSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical class OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical group CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 1
- BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical group CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- OIEFZHJNURGFFI-UHFFFAOYSA-N n-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(NC(C)=O)=C1 OIEFZHJNURGFFI-UHFFFAOYSA-N 0.000 description 1
- GVDGPLKPIVNCEG-UHFFFAOYSA-N n-[2-iodo-5-methoxy-4-[1-(2,2,2-trifluoroacetyl)piperidine-4-carbonyl]phenyl]acetamide Chemical compound COC1=CC(NC(C)=O)=C(I)C=C1C(=O)C1CCN(C(=O)C(F)(F)F)CC1 GVDGPLKPIVNCEG-UHFFFAOYSA-N 0.000 description 1
- ZBHGTXVUPLTJNK-UHFFFAOYSA-N n-[3-methoxy-4-[1-(2,2,2-trifluoroacetyl)piperidine-4-carbonyl]phenyl]acetamide Chemical compound COC1=CC(NC(C)=O)=CC=C1C(=O)C1CCN(C(=O)C(F)(F)F)CC1 ZBHGTXVUPLTJNK-UHFFFAOYSA-N 0.000 description 1
- NAEMCKIYMQQYED-UHFFFAOYSA-N n-[5-methoxy-4-[1-(2,2,2-trifluoroacetyl)piperidine-4-carbonyl]-2-(2-trimethylsilylethynyl)phenyl]acetamide Chemical compound COC1=CC(NC(C)=O)=C(C#C[Si](C)(C)C)C=C1C(=O)C1CCN(C(=O)C(F)(F)F)CC1 NAEMCKIYMQQYED-UHFFFAOYSA-N 0.000 description 1
- RRHNGIRRWDWWQQ-UHFFFAOYSA-N n-iodoaniline Chemical compound INC1=CC=CC=C1 RRHNGIRRWDWWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- PHXHRAOVMXOPIC-UHFFFAOYSA-N piperidine-4-carbonyl chloride Chemical class ClC(=O)C1CCNCC1 PHXHRAOVMXOPIC-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000012949 viral dilated cardiomyopathy Diseases 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Definitions
- the invention relates to treating various disorders associated with enhanced activity of kinase p38- ⁇ . More specifically, it concerns indole-type derivatives useful in these methods.
- cytokines participate in this response, including IL-1, IL-6, IL-8 and TNF. It appears that the activity of these cytokines in the regulation of inflammation rely at least in part on the activation of an enzyme on the cell signaling pathway, a member of the MAP kinase family generally known as p38 and alternatively known as CSBP and RK. This kinase is activated by dual phosphorylation after stimulation by physiochemical stress, treatment with lipopolysaccharides or with proinflammatory cytokines such as IL-1 and TNF. Therefore, inhibitors of the kinase activity of p38 are useful anti-inflammatory agents.
- Eye diseases associated with a fibroproliferative condition include retinal reattachment surgery accompanying proliferative vitreoretinopathy, cataract extraction with intraocular lens implantation, and post glaucoma drainage surgery.
- rheumatoid arthritis rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions
- sepsis septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, asthma, adult respiratory distress syndrome, stroke, reperfusion injury, CNS injuries such as neural trauma and ischemia, psoriasis, restenosis, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases such as osteoporosis, graft-versus-host reaction, Crohn's Disease, ulcerative colitis including inflammatory bowel disease (IBD) and pyresis.
- IBD inflammatory bowel disease
- the invention is directed to methods and compounds useful in treating conditions that are characterized by enhanced p38- ⁇ activity. These conditions include inflammation, proliferative diseases, and certain cardiovascular disorders as well as Alzheimer's disease as further described below.
- the invention is further directed to methods of treating inflammation or proliferative conditions using these compounds.
- the invention is also directed to treating conditions associated with cardiac failure and Alzheimer's disease using the invention compounds.
- the compounds of formula (1) are useful in treating conditions which are characterized by overactivity of p38 kinase, in particular the ⁇ -isoform.
- Conditions “characterized by enhanced p38- ⁇ activity” include those where this enzyme is present in increased amount or wherein the enzyme has been modified to increase its inherent activity, or both.
- enhanced activity refers to any condition wherein the effectiveness of these proteins is undesirably high, regardless of the cause.
- the compounds of the invention are useful in conditions where p38- ⁇ kinase shows enhanced activity. These conditions are those in which fibrosis and organ sclerosis are caused by, or accompanied by, inflammation, oxidation injury, hypoxia, altered temperature or extracellular osmolarity, conditions causing cellular stress, apoptosis or necrosis. These conditions include ischemia-reperfusion injury, congestive heart failure, progressive pulmonary and bronchial fibrosis, hepatitis, arthritis, inflammatory bowel disease, glomerular sclerosis, interstitial renal fibrosis, chronic scarring diseases of the eyes, bladder and reproductive tract, bone marrow dysplasia, chronic infectious or autoimmune states, spinal chord injury and traumatic or surgical wounds. These conditions, of course, would be benefited by compounds which inhibit p38- ⁇ . Methods of treatment with the compounds of the invention are further discussed below.
- the compounds useful in the invention are derivatives of indole-type compounds containing a mandatory substituent, A, at a position corresponding to the 2- or 3-position of indole.
- A a mandatory substituent
- an indole-type nucleus is preferred, although alternatives within the scope of the invention are also illustrated below.
- a “noninterfering substituent” is a substituent which leaves the ability of the compound of formula (1) to inhibit p38- ⁇ activity qualitatively intact. Thus, the substituent may alter the degree of inhibition of p38- ⁇ . However, as long as the compound of formula (1) retains the ability to inhibit p38- ⁇ activity, the substituent will be classified as “noninterfering.”
- a number of assays for determining the ability of any compound to inhibit p38- ⁇ activity are available in the art. A whole blood assay for this evaluation is illustrated below. The gene for p38- ⁇ has been cloned and the protein can be prepared recombinantly and its activity assessed, including an assessment of the ability of an arbitrarily chosen compound to interfere with this activity.
- L 1 and L 2 are described herein as linkers.
- the nature of such linkers is less important than the distance they impart between the portions of the molecule.
- Typical linkers include alkylene, i.e. (CH 2 ) n —R; alkenylene—i.e., an alkylene moiety which contains a double bond, including a double bond at one terminus.
- Other suitable linkers include, for example, substituted alkylenes or alkenylenes, carbonyl moieties, and the like.
- hydrocarbyl residue refers to a residue which contains only carbon and hydrogen.
- the residue may be aliphatic or aromatic, straight-chain, cyclic, branched, saturated or unsaturated.
- the hydrocarbyl residue when so stated however, may contain heteroatoms over and above the carbon and hydrogen members of the substituent residue.
- the hydrocarbyl residue when specifically noted as containing such heteroatoms, may also contain carbonyl groups, amino groups, hydroxyl groups and the like, or contain heteroatoms within the “backbone” of the hydrocarbyl residue.
- organic residue refers to a residue that does not contain carbon. Examples include, but are not limited to, halo, hydroxy, NO 2 or NH 2 .
- alkyl As used herein, the term “alkyl,” “alkenyl” and “alkynyl” include straight- and branched-chain and cyclic monovalent substituents. Examples include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl, 2-propenyl, 3-butynyl, and the like.
- the alkyl, alkenyl and alkynyl substituents contain 1-10C (alkyl) or 2-10C (alkenyl or alkynyl). Preferably they contain 1-6C (alkyl) or 2-6C (alkenyl or alkynyl).
- Heteroalkyl, heteroalkenyl and heteroalkynyl are similarly defined but may contain 1-2 O, S or N heteroatoms or combinations thereof within the backbone residue.
- acyl encompasses the definitions of alkyl, alkenyl, alkynyl and the related heteroforms which are coupled to an additional residue through a carbonyl group.
- “Aromatic” moiety refers to a monocyclic or fused bicyclic moiety such as phenyl or naphthyl; “heteroaromatic” also refers to monocyclic or fused bicyclic ring systems containing one or more heteroatoms selected from O, S and N. The inclusion of a heteroatom permits inclusion of 5-membered rings as well as 6-membered rings.
- typical aromatic systems include pyridyl, pyrimidyl, indolyl, benzimidazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl and the like.
- Any monocyclic or fused ring bicyclic system which has the characteristics of aromaticity in terms of electron distribution throughout the ring system is included in this definition.
- the ring systems contain 5-12 ring member atoms.
- arylalkyl and heteroalkyl refer to aromatic and heteroaromatic systems which are coupled to another residue through a carbon chain, including substituted or unsubstituted, saturated or unsaturated, carbon chains, typically of 1-6C. These carbon chains may also include a carbonyl group, thus making them able to provide substituents as an acyl moiety.
- the invention includes optically pure forms as well as mixtures of stereoisomers or enantiomers.
- linkers L 2 and L 1 in combination with the moiety —X—, provide for separation of the atom of Ar bonded to L 2 from the atom of the ring a bonded to L 1 by a defined minimum number of covalent bond distances counted end-to-end through the compound, as opposed to a measurement of linear distance through space. More particularly, the smallest number of bonds counted end-to-end in the compound separating the atom of Ar bonded to L 2 from the atom of the ring a bonded to L 1 is at least 5, and preferably from 6 to 12, wherein the length of each of such bonds is 1.2 to 2.0 angstroms.
- the linear distance measured through space from the atom of Ar bonded to L 2 to the atom of the ring a bonded to L 1 is a distance of 4.5-24 ⁇ , preferably 6-20 ⁇ , and more preferably 7.5-10 ⁇ .
- L 1 and L 2 are CO and isosteres thereof, or optionally substituted isosteres, or longer chain forms.
- L 2 in particular, may be alkylene or alkenylene optionally substituted with noninterfering substituents or L 1 or L 2 may be or may include a heteroatom such as N, S or O.
- substituents include, but are limited to, a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR 2 , SR, SOR, SO 2 R, OCOR, NRCOR, NRCONR 2 , NRCOOR, OCONR 2 , RCO, COOR, alkyl-COOR, SO 3 R, CONR 2 , SO 2 NR 2 , NRSO 2 NR 2 , CN, CF 3 , R 3 Si, and NO 2 , wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof, and wherein two substituents on L 2 can be joined to form a non-aromatic saturated or unsaturated ring that includes 0-3 hetero
- Isosteres of CO and CH 2 include SO, SO 2 , or CHOH. CO and CH 2 are preferred.
- L is substituted with 0-2 substituents.
- two optional substituents on L 2 can be joined to form a non-aromatic saturated or unsaturated hydrocarbyl ring that includes 0-3 heteroatoms such as O, S and/or N and which contains 3 to 8 members.
- Two optional substituents on L 2 can be joined to form a carbonyl moiety which can be subsequently converted to an oxime, an oximeether, an oximeester, or a ketal.
- Ar is aryl, heteroaryl, including 6-5 fused heteroaryl, cycloaliphatic or cycloheteroaliphatic that can be optionally substituted. Ar is preferably optionally substituted phenyl.
- Each substituent on Ar is independently a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and N, or is an inorganic residue.
- Preferred substituents include those selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR 2 , SR, SOR, SO 2 R, OCOR, NRCOR, NRCONR 2 , NRCOOR, OCONR 2 , RCO, COOR, alkyl-COOR, SO 3 R, CONR 2 , SO 2 NR 2 , NRSO 2 NR 2 , CN, CF 3 , R 3 Si, and NO 2 , wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms
- substituents include halo, alkyl (1-4C) and more preferably, fluoro, chloro and methyl. These substituents may occupy all available positions of the aryl ring of Ar, preferably 1-2 positions, most preferably one position. These substituents may be optionally substituted with substituents similar to those listed. Of course some substituents, such as halo, are not further substituted, as known to one skilled in the art.
- Two adjacent substituents on Ar can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members.
- Moiety —X— in the compound of formula (I) is an aliphatic monocyclic or aliphatic polycyclic moiety optionally comprising one or more hetero ring atoms wherein the cyclic moiety may be optionally substituted with one or more noninterfering substituents and where said optional substituents may constitute a ring fused to X.
- Moiety —X— includes bridged cyclic moieties. Examples of cyclic moieties that may serve as moiety X include:
- —X— in compound (I) are cyclic moieties such that the portion of the compound represented by L 2 -X-L 1 is selected from the group consisting of:
- the noninterfering substituents R 5 include, without limitation, halo, alkyl, alkoxy, aryl, arylalkyl, aryloxy, heteroaryl, acyl, carboxy, or hydroxy.
- R 5 is H, alkyl, OR, NR 2 , SR or halo, where R is H or alkyl.
- R 5 can be joined with an R 1 substituent (defined below) to form an optionally substituted non-aromatic saturated or unsaturated hydrocarbyl ring which contains 3-8 members and 0-3 heteroatoms such as O, N and/or S.
- Preferred embodiments include compounds wherein Z 1 is CH or N, and those wherein both l and k are 1.
- Substituents R 2 and R 3 optionally bonded to the moiety —X— represent independently a noninterfering substituent such as a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and N.
- R 2 and R 3 are independently alkyl, alkoxy, aryl, arylalkyl, aryloxy, heteroalkyl, heteroaryl, heteroarylalkyl, RCO, ⁇ O, acyl, halo, CN, OR, NRCOR, NR, wherein R is H, alkyl (preferably 1-4C), aryl, or hetero forms thereof.
- Each appropriate substituent is itself unsubstituted or substituted with 1-3 substituents.
- the substituents are preferably independently selected from a group that includes alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR 2 , SR, SOR, SO 2 R, OCOR, NRCOR, NRCONR 2 , NRCOOR, OCONR 2 , RCO, COOR, alkyl-COOR, SO 3 R, CONR 2 , SO 2 NR 2 , NRSO 2 NR 2 , CN, CF 3 , R 3 Si, and NO 2 , wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and two of R 2 and/or R 3 on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which
- R 2 and R 3 comprise alkyl (1-4C) especially two alkyl substituents and carbonyl. Most preferably R 2 and R 3 comprise methyl groups or carbonyl groups.
- the —X— moiety may be chiral, hence an isolated enantiomer may be preferred.
- R 1 represents a noninterfering substituent.
- substituents include hydrocarbyl residues (1-6C) containing 0-2 heteroatoms selected from O, S and/or N and inorganic residues.
- n is an integer of 0-3, preferably 0 or 1.
- the substituents represented by R 1 are independently halo, alkyl, heteroalkyl, OCOR, OR, NRCOR, SR, or NR 2 , wherein R is H, alkyl, aryl, or heteroforms thereof. More preferably R 1 substituents are selected from alkyl, alkoxy or halo, and most preferably methoxy, methyl, and chloro.
- n is 0 and the ⁇ ring is unsubstituted, except for L 1 or n is 1 and R 3 is halo or methoxy.
- Z 3 may be NR 5 or O— i.e., the compounds may be related to indole or benzofuran.
- C 3 is NR 5
- preferred embodiments of R 5 include H or optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, or is SOR, SO 2 R, RCO, COOR, alkyl-COR, SO 3 R, CONR 2 , SO 2 NR 2 , CN, CF 3 , NR 2 , OR, alkyl-SR, alkyl-SOR, alkyl-SO 2 R, alkyl-OCOR, alkyl-COOR, alkyl-CN, alkyl-CONR 2 , or R 3 Si, wherein each R is independently H, alkyl, alkenyl or aryl
- R 5 is hydrogen or is alkyl (1-4C), preferably methyl or is acyl (1-4C), or is COOR wherein R is H, alkyl, alkenyl of aryl or hetero forms thereof.
- R 5 is also preferably a substituted alkyl wherein the preferred substituents are form ether linkages or contain sulfinic or sulfonic acid moieties.
- Other preferred substituents include sulfhydryl substituted alkyl substituents.
- Still other preferred substituents include CONR 2 wherein R is defined as above.
- the mandatory substituent CA or CR 2 A is in the 3-position; however, regardless of which position this substituent occupies, the other position is CR 3 , CR 3 2 , NR 4 or N.
- CR 3 is preferred.
- Preferred embodiments of R 3 include hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR 2 , SR, SOR, SO 2 R, OCOR, NRCOR, NRCONR 2 , NRCOOR, OCONR 2 , RCO, COOR, alkyl-COOR, SO 3 R, CONR 2 , SO 2 NR 2 , NRSO 2 NR 2 , CN, CF 3 , R 3 Si, and NO 2 , wherein each R is independently H, alkyl, al
- R 3 is H, alkyl, such as methyl, most preferably, the ring labeled ⁇ contains a double bond and CR 3 is CH or C-alkyl.
- Other preferable forms of R 3 include H, alkyl, acyl, aryl, arylalkyl, heteroalkyl, heteroaryl, halo, OR, NR 2 , SR, NRCOR, alkyl-COOR, RCO, COOR, and CN, wherein each R is independently H, alkyl, or aryl or heteroforms thereof.
- R 4 While the position not occupied by CA is preferred to include CR 3 , the position can also be N or NR 4 . While NR 4 is less preferred (as in that case the ring labeled ⁇ would be saturated), if NR 4 is present, preferred embodiments of R 4 include H, or alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, or is SOR, SO 2 R, RCO, COOR, alkyl-COR, SO 3 R, CONR 2 , SO 2 NR 2 , CN, CF 3 , or R 3 Si wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof.
- CR 2 A or CA occupy position 3- and preferably Z 2 in that position is CA.
- preferred embodiments for R 2 include H, halo, alkyl, alkenyl and the like.
- R 2 is a relatively small substituent corresponding, for example, to H or lower alkyl 1-4C.
- A is -W i -COX j Y wherein Y is COR 6 or an isostere thereof and R 6 is a noninterfering substituent.
- W and X is a spacer and may be, for example, optionally substituted alkyl, alkenyl, or alkynyl, each of i and j is 0 or 1.
- W and X are unsubstituted.
- j is 0 so that the two carbonyl groups are adjacent to each other.
- i is 0 so that the proximal CO is adjacent the ring.
- the noninterfering substituent represented by R 6 when R 6 is other than H, is a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and/or N or is an inorganic residue.
- R 6 is H, or is straight or branched chain alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, or heteroarylalkyl, each optionally substituted with halo, alkyl, heteroalkyl, SR, OR, NR 2 , OCOR, NRCOR, NRCONR 2 , NRSO 2 R, NRSO 2 NR 2 , OCONR 2 , CN, COOR, CONR 2 , COR, or R 3 Si wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof, or wherein R 6 is OR, NR 2 , SR, NRCONR 2
- R 6 are H, heteroarylalkyl, —NR 2 , heteroaryl, —COOR, —NHRNR 2 , heteroaryl-COOR, heteroaryloxy, —OR, heteroaryl-NR 2 , —NROR and alkyl.
- R 6 is isopropyl piperazinyl, methyl piperazinyl, dimethylamine, piperazinyl, isobutyl carboxylate, oxycarbonylethyl, morpholinyl, aminoethyldimethylamine, isobutyl carboxylate piperazinyl, oxypiperazinyl, ethylcarboxylate piperazinyl, methoxy, ethoxy, hydroxy, methyl, amine, aminoethyl pyrrolidinyl, aminopropanediol, piperidinyl, pyrrolidinyl-piperidinyl, or methyl piperidinyl.
- Isosteres of COR 6 as represented by Y are defined as follows.
- isosteres include tetrazole, 1,2,3-triazole, 1,2,4-triazole and imidazole.
- the compounds of formula (1) may be supplied in the form of their pharmaceutically acceptable acid-addition salts including salts of inorganic acids such as hydrochloric, sulfuric, hydrobromic, or phosphoric acid or salts of organic acids such as acetic, tartaric, succinic, benzoic, salicylic, and the like. If a carboxyl moiety is present on the compound of formula (1), the compound may also be supplied as a salt with a pharmaceutically acceptable cation.
- the piperadinyl moiety is generalized to X in formula (I) above where X is an aliphatic monocyclic or aliphatic polycyclic moiety optionally comprising one or more hetero ring atoms wherein the cyclic moiety may be optionally substituted with one or more noninterfering substituents and where said optional substituents may constitute a ring fused to X.
- the indole-type moiety may be generalized as:
- Substituted amino benzoic acid esters such as I can be treated with reagents such as thiomethylacetylaldehyde dimethyl acetal and N-chlorosuccinamide in methylene chloride at low temperature followed by the treatment with a base such as triethylamine at reflux in methylene chloride, dichloroethane or chloroform to give indoles II, Scheme 1.
- reagents such as Raney-Nickel in an appropriate solvent such as ethanol, methanol or isopropanol will yield the corresponding indole carboxylic acid ester which when hydrolyzed under base conditions will give the desired substituted indole carboxylic acid.
- piperidone VIII could be replaced in the above reaction scheme in a known manner with suitable cyclic moieties correspondingly generally to X as defined in the above formula (1) such that instead of the 4-benzylpiperidone of formula IX, a moiety is obtained having the generalized structure
- substituted piperazines XIII can be reacted with various and appropriate ArL 2 X in the presence or absence of a base or other catalytic reagent to give the substituted piperazines XV, Scheme 6, as described in commonly assigned U.S. Ser. No. 09/575,060; compounds comprising the moiety “X” in formula (1) above can also be reacted with ArL 2 X in a known manner to obtain analogs of compound XV in which the cyclic portion thereof is replaced with X in formula (1) above.
- Compounds XV having a chiral center can be further resolved to the chiral components with the use of a chiral resolving agent such as tartaric acid to give either enantiomers of the substituted compounds XV.
- the TNF- ⁇ production correlates to the activity of p38- ⁇ kinase.
- Venous blood is collected from healthy male volunteers into a heparinized syringe and is used within 2 hours of collection.
- Test compounds are dissolved in 100% DMSO and 1 ⁇ l aliquots of drug concentrations ranging from 0 to 1 mM are dispensed into quadruplicate wells of a 24-well microtitre plate (Nunclon Delta SI, Applied Scientific, So. San Francisco, Calif.).
- Whole blood is added at a volume of 1 ml/well and the mixture is incubated for 15 minutes with constant shaking (Titer Plate Shaker, Lab-Line Instruments, Inc., Melrose Park, Ill.) at a humidified atmosphere of 5% CO 2 at 37° C.
- the enriched mononuclear cell assay begins with cryopreserved Human Peripheral Blood Mononuclear Cells (HPBMCs) (Clonetics Corp.) that are rinsed and resuspended in a warm mixture of cell growth media. The resuspended cells are then counted and seeded at 1 ⁇ 10 6 cells/well in a 24-well microtitre plate. The plates are then placed in an incubator for an hour to allow the cells to settle in each well.
- HPBMCs Human Peripheral Blood Mononuclear Cells
- each well contains HPBMCs, LPS and a test chemical compound.
- LPS Lipopolysaccharide
- ELISA Enzyme Linked Immunoassay
- IC 50 values are calculated using the concentration of inhibitor that causes a 50% decrease as compared to a control.
- the compounds of the invention are useful among other indications in treating conditions associated with inflammation.
- the compounds of formula (1) or their pharmaceutically acceptable salts are used in the manufacture of a medicament for prophylactic or therapeutic treatment of mammals, including humans, in respect of conditions characterized by excessive production of cytokines and/or inappropriate or unregulated cytokine activity on such cells as cardiomyocytes, cardiofibroblasts and macrophages.
- the compounds of the invention inhibit the production of cytokines such as TNF, IL-1, IL-6 and IL-8, cytokines that are important proinflammatory constituents in many different disease states and syndromes. Thus, inhibition of these cytokines has benefit in controlling and mitigating many diseases.
- the compounds of the invention are shown herein to inhibit a member of the MAP kinase family variously called p38 MAPK (or p38), CSBP, or SAPK-2. The activation of this protein has been shown to accompany exacerbation of the diseases in response to stress caused, for example, by treatment with lipopolysaccharides or cytokines such as TNF and IL-1.
- Inhibition of p38 activity is predictive of the ability of a medicament to provide a beneficial effect in treating diseases such as Alzheimer's, coronary artery disease, congestive heart failure, cardiomyopathy, myocarditis, vasculitis, restenosis, such as occurs following coronary angioplasty, atherosclerosis, IBD, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, multiple sclerosis, acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), silicosis, pulmonary sarcosis, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, heart and brain failure (stroke) that are characterized by ischemia and reperfusion injury, surgical procedures, such as transplantation procedures and graft rejections, cardiopulmonary bypass, coronary artery bypass graft, CNS injuries, including open and closed head
- p38 has been shown to comprise a group of MAP kinases designated p38- ⁇ , p38- ⁇ , p38- ⁇ and p38- ⁇ .
- Jiang, Y., et al., J Biol Chem (1996) 271:17920-17926 reported characterization of p38- ⁇ as a 372-amino acid protein closely related to p38- ⁇ .
- p38- ⁇ was preferentially activated by MAP kinase kinase-6 (MKK6) and preferentially activated transcription factor 2, thus suggesting that separate mechanisms for action may be associated with these forms.
- MKK6 MAP kinase kinase-6
- ATF-2 activated transcription factor-2
- ⁇ -selective inhibitors would be useful for conditions associated with cachexia attributed to TNF or other conditions such as cancer, infection, or autoimmune disease.
- the invention encompasses the use of compounds which selectively inhibit the activity of the p38- ⁇ isoform for treating conditions associated with activation of p38- ⁇ , in particular those associated with cardiac hypertrophy, ischemia or other environmental stress such as oxidation injury, hyperosmolarity or other agents or factors that activate p38- ⁇ kinase, or cardiac failure, for example, congestive heart failure, cardiomyopathy and myocarditis.
- the manner of administration and formulation of the compounds useful in the invention and their related compounds will depend on the nature of the condition, the severity of the condition, the particular subject to be treated, and the judgment of the practitioner; formulation will depend on mode of administration.
- the compounds of the invention are small molecules, they are conveniently administered by oral administration by compounding them with suitable pharmaceutical excipients so as to provide tablets, capsules, syrups, and the like.
- suitable formulations for oral administration may also include minor components such as buffers, flavoring agents and the like.
- the amount of active ingredient in the formulations will be in the range of 5%-95% of the total formulation, but wide variation is permitted depending on the carrier.
- Suitable carriers include sucrose, pectin, magnesium stearate, lactose, peanut oil, olive oil, water, and the like.
- the compounds useful in the invention may also be administered through suppositories or other transmucosal vehicles.
- formulations will include excipients that facilitate the passage of the compound through the mucosa such as pharmaceutically acceptable detergents.
- the compounds may also be administered topically, for topical conditions such as psoriasis, or in formulation intended to penetrate the skin.
- topical conditions such as psoriasis
- formulation intended to penetrate the skin include lotions, creams, ointments and the like which can be formulated by known methods.
- the compounds may also be administered by injection, including intravenous, intramuscular, subcutaneous or intraperitoneal injection.
- Typical formulations for such use are liquid formulations in isotonic vehicles such as Hank's solution or Ringer's solution.
- Alternative formulations include nasal sprays, liposomal formulations, slow-release formulations, and the like, as are known in the art.
- Any suitable formulation may be used.
- a compendium of art-known formulations is found in Remington's Pharmaceutical Sciences , latest edition, Mack Publishing Company, Easton, Pa. Reference to this manual is routine in the art.
- the dosages of the compounds of the invention will depend on a number of factors which will vary from patient to patient. However, it is believed that generally, the daily oral dosage will utilize 0.001-100 mg/kg total body weight, preferably from 0.01-50 mg/kg and more preferably about 0.01 mg/kg-10 mg/kg. The dose regimen will vary, however, depending on the conditions being treated and the judgment of the practitioner.
- the compounds of formula (1) can be administered as individual active ingredients, or as mixtures of several embodiments of this formula.
- the inhibitors of p38 kinase can be used as single therapeutic agents or in combination with other therapeutic agents.
- Drugs that could be usefully combined with these compounds include natural or synthetic corticosteroids, particularly prednisone and its derivatives, monoclonal antibodies targeting cells of the immune system, antibodies or soluble receptors or receptor fusion proteins targeting immune or non-immune cytokines, and small molecule inhibitors of cell division, protein synthesis, or mRNA transcription or translation, or inhibitors of immune cell differentiation or activation.
- the compounds of the invention may be used in humans, they are also available for veterinary use in treating animal subjects.
- the following examples are intended to illustrate but not to limit the invention.
- the compounds prepared below are inhibitors of p38.
- Example 1 compound A solution of Indole 2 (117 mg, 0.306 mMol) in DCM (4 mL) was cooled to 0° C. and a 2.0 M solution of oxalyl chloride (0.31 mL) in DCM was added dropwise via syringe. The reaction was stirred at 0° C. for one hour and then allowed to warm to room temperature for one hour. The solvent was removed under vacuum. The solvent was replaced by DCM (4 mL) cooled to 0° C. and a 2.0 M solution of dimethyl amine (0.62 mL) in DCM was added via syringe. After 0.5 h the solution was warmed to room temperature and stirred for an additional 30 minutes.
- Triethylamine (7.88 g, 77.9 mMol) was added to a stirred solution of proline methyl ester (5.93 g, 35.4 mMol) in DCM (70 mL).
- the mixture was cooled to 0° C. and 4-fluorobenzoyl chloride (6.18 g, 39.0 mMol) was added slowly via syringe.
- the mixture was stirred for an additional 2 hr at 0° C. and allowed to warm to room temperature for an additional 2 h.
- the solution was then transferred to a separatory funnel, washed with 10% citric acid, 5% potassium carbonate, brine, dried (Na 2 SO 4 ) and concentrated to give a thick oil.
- the residue was purified by flash chromatography to give 5.90 g of the product as a colorless oil.
- Tetraethylenediamine (3.09 g, 26.6 mMol) was added to a solution of lithium diisopropyl amide (2.61 g, 24.4 mMol) in THF (25 mL) at ⁇ 78° C. After the solution was allowed to stir for 15 min, a solution of 1-chloroacetonitrile (2.51 g, 33.3 mL) in THF (6 mL) was added dropwise via addition funnel. The reaction was stirred for an additional 1 h at ⁇ 78° C., warmed to 0° C. and stirred for an additional 30 min. The reaction was then concentrated for form a dark oil, partitioned between DCM-water and the solid was removed by filtration.
- Oxalyl chloride (0.1 mL, 0.2 mMol) was added to a solution of indole in CH 2 Cl 2 (5 mL) at 0° C. The reaction mixture was warmed to rt. slowly, stirred for 5 h, concentrated and then dried for 2 h. The residue was redissolved in CH 2 Cl 2 and quenched with dimethylamine (0.2 mL, 0.4 mMol, 2 M in THF). The reaction mixture was treated with Na 2 CO 3 and extracted with EtOAc. The combined extracts was dried and concentrated. The residue was purified on preparative TLC plate developed with 1% MeOH in EtOAc to give 2 mg of the desired product and 35 mg of the recovered starting material.
- oxalyl chloride (0.72 mMol, 2M in CH 2 Cl 2 ) is added into a 15-ml dry RB flask containing 177 mg of 2,2,2-Trifluoro-1-[4-(6-methoxy-1-methyl-1H-indole-5-carbonyl)-piperidin-1-yl]-ethanone (0.48 mMol) in 2 ml dry CH 2 Cl 2 at 0° C.
- the reaction mixture is stirred at 0° C. for 10 min before being warmed up to room temperature and stirred at room temperature for 1 hour. Excess of oxalyl chloride is removed under vacuo and vacuum dried for 0.5 h.
- reaction mixture was stirred additional 1 hr, then triethylamine (16 mL, 100 mMols) in 30 ml dichloromethane was added dropwise over 5 min, reaction was warmed to room temp, then refluxed for 16 h. Solvent was removed and residue taken up in 500 ml carbon tetrachloride, triethylamine-hydrochloric acid was removed by filtration, filtrate was heated to reflux for 2 h. Solvent was removed by rotary evaporation.
Abstract
Compounds that inhibit p38-α kinase are those wherein a bicyclic aromatic system is coupled through a saturated ring to an aryl group.
Description
- This application is a continuation of U.S. Ser. No. 09/989,991 filed 20 Nov. 2001 and now allowed which claims priority under 35 U.S.C. §119(e) from U.S. Ser. No. 60/252,163 filed 20 Nov. 2000.
- The invention relates to treating various disorders associated with enhanced activity of kinase p38-α. More specifically, it concerns indole-type derivatives useful in these methods.
- A large number of chronic and acute conditions have been recognized to be associated with perturbation of the inflammatory response. A large number of cytokines participate in this response, including IL-1, IL-6, IL-8 and TNF. It appears that the activity of these cytokines in the regulation of inflammation rely at least in part on the activation of an enzyme on the cell signaling pathway, a member of the MAP kinase family generally known as p38 and alternatively known as CSBP and RK. This kinase is activated by dual phosphorylation after stimulation by physiochemical stress, treatment with lipopolysaccharides or with proinflammatory cytokines such as IL-1 and TNF. Therefore, inhibitors of the kinase activity of p38 are useful anti-inflammatory agents.
- Eye diseases associated with a fibroproliferative condition include retinal reattachment surgery accompanying proliferative vitreoretinopathy, cataract extraction with intraocular lens implantation, and post glaucoma drainage surgery.
- PCT applications WO 98/06715, WO 98/07425, and WO 96/40143, all of which are incorporated herein by reference, describe the relationship of p38 kinase inhibitors with various disease states. As mentioned in these applications, inhibitors of p38 kinase are useful in treating a variety of diseases associated with chronic inflammation. These applications list rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, asthma, adult respiratory distress syndrome, stroke, reperfusion injury, CNS injuries such as neural trauma and ischemia, psoriasis, restenosis, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption diseases such as osteoporosis, graft-versus-host reaction, Crohn's Disease, ulcerative colitis including inflammatory bowel disease (IBD) and pyresis.
- The above-referenced PCT applications disclose compounds which are p38 kinase inhibitors said to be useful in treating these disease states. These compounds are either imidazoles or are indoles substituted at the 3- or 4-position with a piperazine ring linked through a carboxamide linkage. Additional compounds which are conjugates of piperazines with indoles are described as insecticides in WO 97/26252, also incorporated herein by reference.
- Certain aroyl/phenyl-substituted piperazines and piperidines which inhibit p38-α kinase are described in PCT publication WO 00/12074 published 9 Mar. 2000. In addition, indolyl substituted piperidines and piperazines which inhibit this enzyme are described in PCT publication No. WO 99/61426 published 2 Dec. 1999. Carbolene derivatives of piperidine and piperazine as p38-α inhibitors are described in PCT/US00/07934 filed 24 Mar. 2000.
- None of the foregoing patents describes the indole derivatives described herein which specifically inhibit p38-α.
- The invention is directed to methods and compounds useful in treating conditions that are characterized by enhanced p38-α activity. These conditions include inflammation, proliferative diseases, and certain cardiovascular disorders as well as Alzheimer's disease as further described below.
-
-
- and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wherein:
- Ar is an aryl group substituted with 0-5 noninterfering substituents, wherein two adjacent noninterfering substituents can form a fused aromatic or nonaromatic ring;
- L1 and L2 are linkers;
- X is an aliphatic monocyclic or aliphatic polycyclic moiety optionally comprising one or more hetero ring atoms wherein the cyclic moiety may be optionally substituted with one or more noninterfering substituents and where said optional substituents may constitute a ring fused to X;
- n is 0-3;
- each R1 is hydrogen or a noninterfering substituent;
represents a single or double bond; - one Z2 is CA or CR2A; the other Z2 is CR3, CR3 2, NR4 or N; and each R2, R3 and R4 is independently hydrogen or a noninterfering substituent;
- Z3 is NR5 or O; where R5 is hydrogen or a noninterfering substituent;
- A is -Wi-COXjY, where Y is COR6 or an isostere thereof, each of W and X is a spacer of 2-6 Å; each of i and j is independently 0 or 1; and R6 is a noninterfering substituent;
- and wherein the smallest number of covalent bonds in the compound separating the atom of Ar linked to L2 and the atom of the α ring linked to L1 is at least 5, each said bond having a bond length of 1.2 to 2.0 angstroms; and/or the distance in space between the atom of Ar linked to L2 and the atom of the a ring linked to L1 is 4.5-24 angstroms.
- and with the proviso that the portion of the compound represented by L2-X-L1 is not:
- where L2 and L1 are linkers; Za is CR or N wherein R is hydrogen or a noninterfering substituent; each Ra is independently a noninterfering substituent; and each of 1 and k is 0-3; and m is 0-4.
- The invention is further directed to methods of treating inflammation or proliferative conditions using these compounds. The invention is also directed to treating conditions associated with cardiac failure and Alzheimer's disease using the invention compounds.
- The compounds of formula (1) are useful in treating conditions which are characterized by overactivity of p38 kinase, in particular the α-isoform. Conditions “characterized by enhanced p38-α activity” include those where this enzyme is present in increased amount or wherein the enzyme has been modified to increase its inherent activity, or both. Thus, “enhanced activity” refers to any condition wherein the effectiveness of these proteins is undesirably high, regardless of the cause.
- The compounds of the invention are useful in conditions where p38-α kinase shows enhanced activity. These conditions are those in which fibrosis and organ sclerosis are caused by, or accompanied by, inflammation, oxidation injury, hypoxia, altered temperature or extracellular osmolarity, conditions causing cellular stress, apoptosis or necrosis. These conditions include ischemia-reperfusion injury, congestive heart failure, progressive pulmonary and bronchial fibrosis, hepatitis, arthritis, inflammatory bowel disease, glomerular sclerosis, interstitial renal fibrosis, chronic scarring diseases of the eyes, bladder and reproductive tract, bone marrow dysplasia, chronic infectious or autoimmune states, spinal chord injury and traumatic or surgical wounds. These conditions, of course, would be benefited by compounds which inhibit p38-α. Methods of treatment with the compounds of the invention are further discussed below.
- The compounds useful in the invention are derivatives of indole-type compounds containing a mandatory substituent, A, at a position corresponding to the 2- or 3-position of indole. In general, an indole-type nucleus is preferred, although alternatives within the scope of the invention are also illustrated below.
- In the description above, certain positions of the molecule are described as permitting “noninterfering substituents.” This terminology is used because the substituents in these positions generally speaking are not relevant to the essential activity of the molecule taken as a whole. A wide variety of substituents can be employed in these positions, and it is well within ordinary skill to determine whether any particular arbitrary substituent is or is not “noninterfering.”
- As used herein, a “noninterfering substituent” is a substituent which leaves the ability of the compound of formula (1) to inhibit p38-α activity qualitatively intact. Thus, the substituent may alter the degree of inhibition of p38-α. However, as long as the compound of formula (1) retains the ability to inhibit p38-α activity, the substituent will be classified as “noninterfering.” A number of assays for determining the ability of any compound to inhibit p38-α activity are available in the art. A whole blood assay for this evaluation is illustrated below. The gene for p38-α has been cloned and the protein can be prepared recombinantly and its activity assessed, including an assessment of the ability of an arbitrarily chosen compound to interfere with this activity. The essential features of the molecule are tightly defined. The positions which are occupied by “noninterfering substituents” can be substituted by conventional organic moieties as is understood in the art. It is irrelevant to the present invention to test the outer limits of such substitutions. The essential features of the compounds are those set forth with particularity herein.
- In addition, L1 and L2 are described herein as linkers. The nature of such linkers is less important than the distance they impart between the portions of the molecule. Typical linkers include alkylene, i.e. (CH2)n—R; alkenylene—i.e., an alkylene moiety which contains a double bond, including a double bond at one terminus. Other suitable linkers include, for example, substituted alkylenes or alkenylenes, carbonyl moieties, and the like.
- As used herein, “hydrocarbyl residue” refers to a residue which contains only carbon and hydrogen. The residue may be aliphatic or aromatic, straight-chain, cyclic, branched, saturated or unsaturated. The hydrocarbyl residue, when so stated however, may contain heteroatoms over and above the carbon and hydrogen members of the substituent residue. Thus, when specifically noted as containing such heteroatoms, the hydrocarbyl residue may also contain carbonyl groups, amino groups, hydroxyl groups and the like, or contain heteroatoms within the “backbone” of the hydrocarbyl residue.
- As used herein, “inorganic residue” refers to a residue that does not contain carbon. Examples include, but are not limited to, halo, hydroxy, NO2 or NH2.
- As used herein, the term “alkyl,” “alkenyl” and “alkynyl” include straight- and branched-chain and cyclic monovalent substituents. Examples include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl, 2-propenyl, 3-butynyl, and the like. Typically, the alkyl, alkenyl and alkynyl substituents contain 1-10C (alkyl) or 2-10C (alkenyl or alkynyl). Preferably they contain 1-6C (alkyl) or 2-6C (alkenyl or alkynyl). Heteroalkyl, heteroalkenyl and heteroalkynyl are similarly defined but may contain 1-2 O, S or N heteroatoms or combinations thereof within the backbone residue.
- As used herein, “acyl” encompasses the definitions of alkyl, alkenyl, alkynyl and the related heteroforms which are coupled to an additional residue through a carbonyl group.
- “Aromatic” moiety refers to a monocyclic or fused bicyclic moiety such as phenyl or naphthyl; “heteroaromatic” also refers to monocyclic or fused bicyclic ring systems containing one or more heteroatoms selected from O, S and N. The inclusion of a heteroatom permits inclusion of 5-membered rings as well as 6-membered rings. Thus, typical aromatic systems include pyridyl, pyrimidyl, indolyl, benzimidazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl and the like. Any monocyclic or fused ring bicyclic system which has the characteristics of aromaticity in terms of electron distribution throughout the ring system is included in this definition. Typically, the ring systems contain 5-12 ring member atoms.
- Similarly, “arylalkyl” and “heteroalkyl” refer to aromatic and heteroaromatic systems which are coupled to another residue through a carbon chain, including substituted or unsubstituted, saturated or unsaturated, carbon chains, typically of 1-6C. These carbon chains may also include a carbonyl group, thus making them able to provide substituents as an acyl moiety.
- When the compounds of Formula 1 contain one or more chiral centers, the invention includes optically pure forms as well as mixtures of stereoisomers or enantiomers.
- With respect to the portion of the compound between the Ar and the ring α, linkers L2 and L1, in combination with the moiety —X—, provide for separation of the atom of Ar bonded to L2 from the atom of the ring a bonded to L1 by a defined minimum number of covalent bond distances counted end-to-end through the compound, as opposed to a measurement of linear distance through space. More particularly, the smallest number of bonds counted end-to-end in the compound separating the atom of Ar bonded to L2 from the atom of the ring a bonded to L1 is at least 5, and preferably from 6 to 12, wherein the length of each of such bonds is 1.2 to 2.0 angstroms. In terms of a linear distance through space, the linear distance measured through space from the atom of Ar bonded to L2 to the atom of the ring a bonded to L1 is a distance of 4.5-24 Å, preferably 6-20 Å, and more preferably 7.5-10 Å.
- Typical, but nonlimiting, embodiments of L1 and L2 are CO and isosteres thereof, or optionally substituted isosteres, or longer chain forms. L2, in particular, may be alkylene or alkenylene optionally substituted with noninterfering substituents or L1 or L2 may be or may include a heteroatom such as N, S or O. Such substituents include, but are limited to, a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-COOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof, and wherein two substituents on L2 can be joined to form a non-aromatic saturated or unsaturated ring that includes 0-3 heteroatoms which are O, S and/or N and which contains 3 to 8 members or said two substituents can be joined to form a carbonyl moiety or an oxime, oximeether, oximeester or ketal of said carbonyl moiety. Further examples of L1 and L2 include —CH2—NH—CO— and —CH2—NH—CO—.
- Isosteres of CO and CH2, include SO, SO2, or CHOH. CO and CH2 are preferred.
- Thus, L is substituted with 0-2 substituents. Where appropriate, two optional substituents on L2 can be joined to form a non-aromatic saturated or unsaturated hydrocarbyl ring that includes 0-3 heteroatoms such as O, S and/or N and which contains 3 to 8 members. Two optional substituents on L2 can be joined to form a carbonyl moiety which can be subsequently converted to an oxime, an oximeether, an oximeester, or a ketal.
- Ar is aryl, heteroaryl, including 6-5 fused heteroaryl, cycloaliphatic or cycloheteroaliphatic that can be optionally substituted. Ar is preferably optionally substituted phenyl.
- Each substituent on Ar is independently a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and N, or is an inorganic residue. Preferred substituents include those selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-COOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof, and wherein two of said optional substituents on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members. More preferred substituents include halo, alkyl (1-4C) and more preferably, fluoro, chloro and methyl. These substituents may occupy all available positions of the aryl ring of Ar, preferably 1-2 positions, most preferably one position. These substituents may be optionally substituted with substituents similar to those listed. Of course some substituents, such as halo, are not further substituted, as known to one skilled in the art.
- Two adjacent substituents on Ar can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members.
- Moiety —X— in the compound of formula (I) is an aliphatic monocyclic or aliphatic polycyclic moiety optionally comprising one or more hetero ring atoms wherein the cyclic moiety may be optionally substituted with one or more noninterfering substituents and where said optional substituents may constitute a ring fused to X. Moiety —X— includes bridged cyclic moieties. Examples of cyclic moieties that may serve as moiety X include:
-
-
- wherein, in each of structures (I) to (IV):
- one or more of the ring carbon atoms not bound to L2 or L1 may be optionally replaced with NR5, where R5 is hydrogen or a noninterfering substituent; or by CHR2 or CR2 2, where R2 is a noninterfering substituent other than hydrogen; and
- one or both of the ring carbon atoms bound to L2 and L1 may be independently replaced with CR or N where R2 is independently a noninterfering substituent other than hydrogen.
- The noninterfering substituents R5 (i.e. when Z3 is NR5) include, without limitation, halo, alkyl, alkoxy, aryl, arylalkyl, aryloxy, heteroaryl, acyl, carboxy, or hydroxy. Preferably, R5 is H, alkyl, OR, NR2, SR or halo, where R is H or alkyl. Additionally, R5 can be joined with an R1 substituent (defined below) to form an optionally substituted non-aromatic saturated or unsaturated hydrocarbyl ring which contains 3-8 members and 0-3 heteroatoms such as O, N and/or S. Preferred embodiments include compounds wherein Z1 is CH or N, and those wherein both l and k are 1.
- Substituents R2 and R3 optionally bonded to the moiety —X— represent independently a noninterfering substituent such as a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and N. Preferably R2 and R3 are independently alkyl, alkoxy, aryl, arylalkyl, aryloxy, heteroalkyl, heteroaryl, heteroarylalkyl, RCO, ═O, acyl, halo, CN, OR, NRCOR, NR, wherein R is H, alkyl (preferably 1-4C), aryl, or hetero forms thereof. Each appropriate substituent is itself unsubstituted or substituted with 1-3 substituents. The substituents are preferably independently selected from a group that includes alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-COOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and two of R2 and/or R3 on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members, or R2 and R3 independently are ═O or an oxime, oximeether, oximeester or ketal thereof. Preferred embodiments of R2 and R3 comprise alkyl (1-4C) especially two alkyl substituents and carbonyl. Most preferably R2 and R3 comprise methyl groups or carbonyl groups. The —X— moiety may be chiral, hence an isolated enantiomer may be preferred.
- R1 represents a noninterfering substituent. Such substituents include hydrocarbyl residues (1-6C) containing 0-2 heteroatoms selected from O, S and/or N and inorganic residues. n is an integer of 0-3, preferably 0 or 1. Preferably, the substituents represented by R1 are independently halo, alkyl, heteroalkyl, OCOR, OR, NRCOR, SR, or NR2, wherein R is H, alkyl, aryl, or heteroforms thereof. More preferably R1 substituents are selected from alkyl, alkoxy or halo, and most preferably methoxy, methyl, and chloro. Most preferably, n is 0 and the α ring is unsubstituted, except for L1 or n is 1 and R3 is halo or methoxy.
- In the ring labeled β, Z3 may be NR5 or O— i.e., the compounds may be related to indole or benzofuran. If C3 is NR5, preferred embodiments of R5 include H or optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, or is SOR, SO2R, RCO, COOR, alkyl-COR, SO3R, CONR2, SO2NR2, CN, CF3, NR2, OR, alkyl-SR, alkyl-SOR, alkyl-SO2R, alkyl-OCOR, alkyl-COOR, alkyl-CN, alkyl-CONR2, or R3Si, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof. More preferably, R5 is hydrogen or is alkyl (1-4C), preferably methyl or is acyl (1-4C), or is COOR wherein R is H, alkyl, alkenyl of aryl or hetero forms thereof. R5 is also preferably a substituted alkyl wherein the preferred substituents are form ether linkages or contain sulfinic or sulfonic acid moieties. Other preferred substituents include sulfhydryl substituted alkyl substituents. Still other preferred substituents include CONR2 wherein R is defined as above.
- It is preferred that the indicated dotted line represents a double bond; however, compounds which contain a saturated β ring are also included within the scope of the invention.
- Preferably, the mandatory substituent CA or CR2A is in the 3-position; however, regardless of which position this substituent occupies, the other position is CR3, CR3 2, NR4 or N. CR3 is preferred. Preferred embodiments of R3 include hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-COOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and two of R3 can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members. Most preferably, R3 is H, alkyl, such as methyl, most preferably, the ring labeled β contains a double bond and CR3 is CH or C-alkyl. Other preferable forms of R3 include H, alkyl, acyl, aryl, arylalkyl, heteroalkyl, heteroaryl, halo, OR, NR2, SR, NRCOR, alkyl-COOR, RCO, COOR, and CN, wherein each R is independently H, alkyl, or aryl or heteroforms thereof.
- While the position not occupied by CA is preferred to include CR3, the position can also be N or NR4. While NR4 is less preferred (as in that case the ring labeled β would be saturated), if NR4 is present, preferred embodiments of R4 include H, or alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, or is SOR, SO2R, RCO, COOR, alkyl-COR, SO3R, CONR2, SO2NR2, CN, CF3, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof.
- Preferably, CR2A or CA occupy position 3- and preferably Z2 in that position is CA. However, if the β ring is saturated and R2 is present, preferred embodiments for R2 include H, halo, alkyl, alkenyl and the like. Preferably R2 is a relatively small substituent corresponding, for example, to H or lower alkyl 1-4C.
- A is -Wi-COXjY wherein Y is COR6 or an isostere thereof and R6 is a noninterfering substituent. Each of W and X is a spacer and may be, for example, optionally substituted alkyl, alkenyl, or alkynyl, each of i and j is 0 or 1. Preferably, W and X are unsubstituted. Preferably, j is 0 so that the two carbonyl groups are adjacent to each other. Preferably, also, i is 0 so that the proximal CO is adjacent the ring. However, compounds wherein the proximal CO is spaced from the ring can readily be prepared by selective reduction of an initially glyoxal substituted β ring. In the most preferred embodiments of the invention, the α/β ring system is an indole containing CA in position 3- and wherein A is COCR6.
- The noninterfering substituent represented by R6, when R6 is other than H, is a hydrocarbyl residue (1-20C) containing 0-5 heteroatoms selected from O, S and/or N or is an inorganic residue. Preferred are embodiments wherein R6 is H, or is straight or branched chain alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, or heteroarylalkyl, each optionally substituted with halo, alkyl, heteroalkyl, SR, OR, NR2, OCOR, NRCOR, NRCONR2, NRSO2R, NRSO2NR2, OCONR2, CN, COOR, CONR2, COR, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof, or wherein R6 is OR, NR2, SR, NRCONR2, OCONR2, or NRSO2NR2, wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof, and wherein two R attached to the same atom may form a 3-8 member ring and wherein said ring may further be substituted by alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, each optionally substituted with halo, SR, OR, NR2, OCOR, NRCOR, NRCONR2, NRSO2R, NRSO2NR2, OCONR2, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl or the heteroatom-containing forms thereof wherein two R attached to the same atom may form a 3-8 member ring, optionally substituted as above defined.
- Other preferred embodiments of R6 are H, heteroarylalkyl, —NR2, heteroaryl, —COOR, —NHRNR2, heteroaryl-COOR, heteroaryloxy, —OR, heteroaryl-NR2, —NROR and alkyl. Most preferably R6 is isopropyl piperazinyl, methyl piperazinyl, dimethylamine, piperazinyl, isobutyl carboxylate, oxycarbonylethyl, morpholinyl, aminoethyldimethylamine, isobutyl carboxylate piperazinyl, oxypiperazinyl, ethylcarboxylate piperazinyl, methoxy, ethoxy, hydroxy, methyl, amine, aminoethyl pyrrolidinyl, aminopropanediol, piperidinyl, pyrrolidinyl-piperidinyl, or methyl piperidinyl.
- Isosteres of COR6 as represented by Y are defined as follows.
- The isosteres have varying lipophilicity and may contribute to enhanced metabolic stability. Thus, Y, as shown, may be replaced by the isosteres in Table 1.
TABLE 1 Acid Isosteres Names of Groups Chemical Structures Substitution Groups (SG) tetrazole n/a 1,2,3-triazole H; SCH3; COCH3; Br; SOCH3; SO2CH3; NO2; CF3; CN; COOMe 1,2,4-triazole H; SCH3; COCH3; Br; SOCH3; SO2CH3; NO2 imidazole H; SCH3; COCH3; Br; SOCH3; SO2CH3; NO2 - Thus, isosteres include tetrazole, 1,2,3-triazole, 1,2,4-triazole and imidazole.
- The compounds of formula (1) may be supplied in the form of their pharmaceutically acceptable acid-addition salts including salts of inorganic acids such as hydrochloric, sulfuric, hydrobromic, or phosphoric acid or salts of organic acids such as acetic, tartaric, succinic, benzoic, salicylic, and the like. If a carboxyl moiety is present on the compound of formula (1), the compound may also be supplied as a salt with a pharmaceutically acceptable cation.
- Synthesis of the Invention Compounds
-
- In the present invention, the piperadinyl moiety is generalized to X in formula (I) above where X is an aliphatic monocyclic or aliphatic polycyclic moiety optionally comprising one or more hetero ring atoms wherein the cyclic moiety may be optionally substituted with one or more noninterfering substituents and where said optional substituents may constitute a ring fused to X.
- As disclosed commonly assigned in U.S. Ser. No. 09/575,060, the glyoxal type substituent at position 3 can be generalized to WiCOXjY.
-
-
- Substituted amino benzoic acid esters such as I can be treated with reagents such as thiomethylacetylaldehyde dimethyl acetal and N-chlorosuccinamide in methylene chloride at low temperature followed by the treatment with a base such as triethylamine at reflux in methylene chloride, dichloroethane or chloroform to give indoles II, Scheme 1. Treatment with reagents such as Raney-Nickel in an appropriate solvent such as ethanol, methanol or isopropanol will yield the corresponding indole carboxylic acid ester which when hydrolyzed under base conditions will give the desired substituted indole carboxylic acid.
- Alternatively, substituted amino benzoic acid esters I can be converted to the ketals IV, Scheme 2, with an appropriate aldehyde under conditions of reductive alkylation with reagents such as sodium triacetoxyborohydride in acetic acid in the presence of sodium sulfate. The amines can then be treated with Lewis acids such as aluminum chloride, titanium chloride, BF3-etherate in dichloromethane or dichloroethane, under reflux to give the corresponding substituted indole methyl esters, with appropriate substitutions.
- Another method could involve the treatment of the substituted amino benzoic acid esters I with iodine and sodium periodate in an appropriate solvent such as dimethylformamide, to give the corresponding iodo aniline V, Scheme 3. This can be coupled with an acetylene such as trimethyl silyl acetylene or ethylethenyl ether in the presence of an appropriate catalysts such as palladium and copper and a base such as triethylamine to give the silyl coupled product such as VI. Subsequent cyclization in a solvent such as dimethylformamide and in the presence of a catalyst such as copper iodide would give the appropriately substituted indoles VII.
- Commonly assigned U.S. Ser. No. 09/575,060 disclosed that piperidine moieties can be obtained by treating an appropriate piperidone such as VIII, Scheme 4, with substituted benzyl phosphonate esters in the presence of a base such as sodium hydride to give alkenes which can be reduced to the corresponding substituted 4-benzylpiperidine such as IX. The hydrogenations are typically done in the presence of catalytic metals in solvents such as methanol, ethanol and ethyl acetate. In the present invention the piperidone VIII could be replaced in the above reaction scheme in a known manner with suitable cyclic moieties correspondingly generally to X as defined in the above formula (1) such that instead of the 4-benzylpiperidone of formula IX, a moiety is obtained having the generalized structure
-
- in which X has the definition given above:
- in which X has the definition given above:
- An alternate method disclosed in Commonly assigned U.S. Ser. No. 09/575,060 could involve isonipecotoyl chlorides such as X which can be used to acylate appropriately substituted benzenes (ArH) in the presence of a Lewis acid such as aluminum chloride to give the ketones XI, Scheme 5. Further modifications of the carbonyl moiety of XI using methods and routes generally known can then lead to the desired compounds XII. In the present invention the cyclic precursor in compound X above can be replaced with cyclic moieties corresponding generally to the monocyclic or polycyclic aliphatic moieties defined as “X” in the above formula (1).
- Moreover, in the same manner that substituted piperazines XIII can be reacted with various and appropriate ArL2X in the presence or absence of a base or other catalytic reagent to give the substituted piperazines XV, Scheme 6, as described in commonly assigned U.S. Ser. No. 09/575,060; compounds comprising the moiety “X” in formula (1) above can also be reacted with ArL2X in a known manner to obtain analogs of compound XV in which the cyclic portion thereof is replaced with X in formula (1) above. Compounds XV having a chiral center can be further resolved to the chiral components with the use of a chiral resolving agent such as tartaric acid to give either enantiomers of the substituted compounds XV.
- Compounds III can be treated with halides, acid chlorides and other electrophiles (BX), Scheme 7, containing a variety of different substituents, in the presence of a base such as sodium hydride, in a variety of different solvents, to give compounds of type XVI. These can then be converted to the corresponding acids XVII by treatment with appropriate reagents such as an aqueous base. As disclosed in commonly assigned U.S. Ser. No. 09/575,060, the acids may then be coupled to substituted amines IX, XII or XV using a coupling agent such as EDAC.HCl in a variety of solvents including methylene chloride, dimethyl formamide, to give compounds XVIII. In accordance with the present invention the piperazine/piperadine component of compound XVIII may be replaced with a cyclic aliphatic moiety “X” as defined in formula (1) above.
- Compounds XVIII, or the analog thereof in which the piperazine/piperazine ring is replaced with “X” in formula (1) above can be first treated with acid chlorides such as oxalyl chloride in methylene chloride under anhydrous conditions followed by treatment with a variety of nucleophiles WH to give compounds of type XIX, Scheme 8.
- Assays for p38 α Kinase Inhibition
- For each of the assay procedures described below, the TNF-α production correlates to the activity of p38-α kinase.
- A. Human Whole Blood Assay for p38 Kinase Inhibition
- Venous blood is collected from healthy male volunteers into a heparinized syringe and is used within 2 hours of collection. Test compounds are dissolved in 100% DMSO and 1 μl aliquots of drug concentrations ranging from 0 to 1 mM are dispensed into quadruplicate wells of a 24-well microtitre plate (Nunclon Delta SI, Applied Scientific, So. San Francisco, Calif.). Whole blood is added at a volume of 1 ml/well and the mixture is incubated for 15 minutes with constant shaking (Titer Plate Shaker, Lab-Line Instruments, Inc., Melrose Park, Ill.) at a humidified atmosphere of 5% CO2 at 37° C. Whole blood is cultured either undiluted or at a final dilution of 1:10 with RPMI 1640 (Gibco 31800+NaHCO3, Life Technologies, Rockville, Md. and Scios, Inc., Sunnyvale, Calif.). At the end of the incubation period, 10 μl of LPS (E. coli 0111:B4, Sigma Chemical Co., St. Louis, Mo.) is added to each well to a final concentration of 1 or 0.1 μg/ml for undiluted or 1:10 diluted whole blood, respectively. The incubation is continued for an additional 2 hours. The reaction is stopped by placing the microtitre plates in an ice bath and plasma or cell-free supernates are collected by centrifugation at 3000 rpm for 10 minutes at 4° C. The plasma samples are stored at −80° C. until assayed for TNF-α levels by ELISA, following the directions supplied by Quantikine Human TNF-α assay kit (R&D Systems, Minneapolis, Minn.).
- IC50 values are calculated using the concentration of inhibitor that causes a 50% decrease as compared to a control.
- B. Enriched Mononuclear Cell Assay for p38 Kinase Inhibition
- The enriched mononuclear cell assay, the protocol of which is set forth below, begins with cryopreserved Human Peripheral Blood Mononuclear Cells (HPBMCs) (Clonetics Corp.) that are rinsed and resuspended in a warm mixture of cell growth media. The resuspended cells are then counted and seeded at 1×106 cells/well in a 24-well microtitre plate. The plates are then placed in an incubator for an hour to allow the cells to settle in each well.
- After the cells have settled, the media is aspirated and new media containing 100 ng/ml of the cytokine stimulatory factor Lipopolysaccharide (LPS) and a test chemical compound is added to each well of the microtitre plate. Thus, each well contains HPBMCs, LPS and a test chemical compound. The cells are then incubated for 2 hours, and the amount of the cytokine Tumor Necrosis Factor Alpha (TNF-α) is measured using an Enzyme Linked Immunoassay (ELISA). One such ELISA for detecting the levels of TNF-α is commercially available from R&D Systems. The amount of TNF-α production by the HPBMCs in each well is then compared to a control well to determine whether the chemical compound acts as an inhibitor of cytokine production.
- LPS Induced Cytokine Synthesis in HPBMCs
-
- Cryopreserved HPBMC (cat#CC-2702 Clonetics Corp)
- LGM-3 media (cat#CC-3212 Clonetics Corp)
- LPS stock 10 μg/ml (Cat. No. L 2630 serotype 0111:B4 Sigma)
- Human TNF-α ELISA (R&D Systems)
- DNase I (10 mg/ml stock)
- Preparation of Cells.
-
- LGM-3 media warmed to 37° C.
- 5 μl of DNase I stock added to 10 ml media.
- Cells thawed rapidly and dispersed into above.
- Centrifuge 200×g×10 min @ RT.
- Pellet up in 10 ml sterile PBS.
- Centrifuge 200×g×10 min @ RT.
- Pellet resuspended in 10 ml LGM-3 then diluted to 50 ml with LGM-3.
- Perform cell count.
- Adjust to 1×E06 cells/well.
- Seed 1 ml/well of a 24 well plate.
- Place plate in incubator to plate down for 1 hour.
- Preparation of Incubation Media.
-
- LGM-3 containing 100 ng/ml LPS (e.g. 50 ml media plus 0.5 ml LPS stock)
- Aliquot into 2 ml aliquots and add 1000× inhibitor dilutions.
- Incubation
- When cells have plated down aspirate media away and overlay with 1 ml relevant incubation media. Return plate to incubator for 2 hours or 24 hours. Remove supernatants after incubation to a labeled tube and either perform TNF (or other) ELISA immediately or freeze for later assay.
- IC50 values are calculated using the concentration of inhibitor that causes a 50% decrease as compared to a control.
- Administration and Use
- The compounds of the invention are useful among other indications in treating conditions associated with inflammation. Thus, the compounds of formula (1) or their pharmaceutically acceptable salts are used in the manufacture of a medicament for prophylactic or therapeutic treatment of mammals, including humans, in respect of conditions characterized by excessive production of cytokines and/or inappropriate or unregulated cytokine activity on such cells as cardiomyocytes, cardiofibroblasts and macrophages.
- The compounds of the invention inhibit the production of cytokines such as TNF, IL-1, IL-6 and IL-8, cytokines that are important proinflammatory constituents in many different disease states and syndromes. Thus, inhibition of these cytokines has benefit in controlling and mitigating many diseases. The compounds of the invention are shown herein to inhibit a member of the MAP kinase family variously called p38 MAPK (or p38), CSBP, or SAPK-2. The activation of this protein has been shown to accompany exacerbation of the diseases in response to stress caused, for example, by treatment with lipopolysaccharides or cytokines such as TNF and IL-1. Inhibition of p38 activity, therefore, is predictive of the ability of a medicament to provide a beneficial effect in treating diseases such as Alzheimer's, coronary artery disease, congestive heart failure, cardiomyopathy, myocarditis, vasculitis, restenosis, such as occurs following coronary angioplasty, atherosclerosis, IBD, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, multiple sclerosis, acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), silicosis, pulmonary sarcosis, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, heart and brain failure (stroke) that are characterized by ischemia and reperfusion injury, surgical procedures, such as transplantation procedures and graft rejections, cardiopulmonary bypass, coronary artery bypass graft, CNS injuries, including open and closed head trauma, inflammatory eye conditions such as conjunctivitis and uveitis, acute renal failure, glomerulonephritis, inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis, graft vs. host disease, bone resorption diseases like osteoporosis, type II diabetes, pyresis, psoriasis, cachexia, viral diseases such as those caused by HIV, CMV, and Herpes, and cerebral malaria.
- Within the last several years, p38 has been shown to comprise a group of MAP kinases designated p38-α, p38-β, p38-γ and p38-δ. Jiang, Y., et al., J Biol Chem (1996) 271:17920-17926 reported characterization of p38-β as a 372-amino acid protein closely related to p38-α. In comparing the activity of p38-α with that of p38-β, the authors state that while both are activated by proinflammatory cytokines and environmental stress, p38-β was preferentially activated by MAP kinase kinase-6 (MKK6) and preferentially activated transcription factor 2, thus suggesting that separate mechanisms for action may be associated with these forms.
- Kumar, S., et al., Biochem Biophys Res Comm (1997) 235:533-538 and Stein, B., et al., J Biol Chem (1997) 272: 19509-19517 reported a second isoform of p38-β, p38-β2, containing 364 amino acids with 73% identity to p38-α. All of these reports show evidence that p38-β is activated by proinflammatory cytokines and environmental stress, although the second reported p38-β isoform, p38-β2, appears to be preferentially expressed in the CNS, heart and skeletal muscle compared to the more ubiquitous tissue expression of p38-α. Furthermore, activated transcription factor-2 (ATF-2) was observed to be a better substrate for p38-β2 than for p38-α, thus suggesting that separate mechanisms of action may be associated with these forms. The physiological role of p38-β1 has been called into question by the latter two reports since it cannot be found in human tissue and does not exhibit appreciable kinase activity with the substrates of p38-α.
- The identification of p38-γ was reported by Li, Z., et al., Biochem Biophys Res Comm (1996) 228:334-340 and of p38-δ by Wang, X., et al., J Biol Chem (1997) 272:23668-23674 and by Kumar, S., et al., Biochem Biophys Res Comm (1997) 235:533-538. The data suggest that these two p38 isoforms (γ and δ) represent a unique subset of the MAPK family based on their tissue expression patterns, substrate utilization, response to direct and indirect stimuli, and susceptibility to kinase inhibitors.
- Various results with regard to response to drugs targeting the p38 family as between p38-α and either the putative p38-β1 or p38-β2 or both were reported by Jiang, Kumar, and Stein cited above as well as by Eyers, P. A., et al., Chem and Biol (1995) 5:321-328. An additional paper by Wang, Y., et al., J Biol Chem (1998) 273:2161-2168 suggests the significance of such differential effects. As pointed out by Wang, a number of stimuli, such as myocardial infarction, hypertension, valvular diseases, viral myocarditis, and dilated cardiomyopathy lead to an increase in cardiac workload and elevated mechanical stress on cardiomyocytes. These are said to lead to an adaptive hypertrophic response which, if not controlled, has decidedly negative consequences. Wang cites previous studies which have shown that in ischemia reperfusion treated hearts, p38 MAPK activities are elevated in association with hypertrophy and programmed cell death. Wang shows in the cited paper that activation of p38-β activity results in hypertrophy, whereas activation of p38-α activity leads to myocyte apoptosis. Thus, selective inhibition of p38-α activity as compared to p38-β activity will be of benefit in treating conditions associated with cardiac failure. These conditions include congestive heart failure, cardiomyopathy, myocarditis, vasculitis, vascular restenosis, valvular disease, conditions associated with cardiopulmonary bypass, coronary artery bypass, grafts and vascular grafts. Further, to the extent that the α-isoform is toxic in other muscle cell types, α-selective inhibitors would be useful for conditions associated with cachexia attributed to TNF or other conditions such as cancer, infection, or autoimmune disease.
- Thus, the invention encompasses the use of compounds which selectively inhibit the activity of the p38-α isoform for treating conditions associated with activation of p38-α, in particular those associated with cardiac hypertrophy, ischemia or other environmental stress such as oxidation injury, hyperosmolarity or other agents or factors that activate p38-α kinase, or cardiac failure, for example, congestive heart failure, cardiomyopathy and myocarditis.
- The manner of administration and formulation of the compounds useful in the invention and their related compounds will depend on the nature of the condition, the severity of the condition, the particular subject to be treated, and the judgment of the practitioner; formulation will depend on mode of administration. As the compounds of the invention are small molecules, they are conveniently administered by oral administration by compounding them with suitable pharmaceutical excipients so as to provide tablets, capsules, syrups, and the like. Suitable formulations for oral administration may also include minor components such as buffers, flavoring agents and the like. Typically, the amount of active ingredient in the formulations will be in the range of 5%-95% of the total formulation, but wide variation is permitted depending on the carrier. Suitable carriers include sucrose, pectin, magnesium stearate, lactose, peanut oil, olive oil, water, and the like.
- The compounds useful in the invention may also be administered through suppositories or other transmucosal vehicles. Typically, such formulations will include excipients that facilitate the passage of the compound through the mucosa such as pharmaceutically acceptable detergents.
- The compounds may also be administered topically, for topical conditions such as psoriasis, or in formulation intended to penetrate the skin. These include lotions, creams, ointments and the like which can be formulated by known methods.
- The compounds may also be administered by injection, including intravenous, intramuscular, subcutaneous or intraperitoneal injection. Typical formulations for such use are liquid formulations in isotonic vehicles such as Hank's solution or Ringer's solution.
- Alternative formulations include nasal sprays, liposomal formulations, slow-release formulations, and the like, as are known in the art.
- Any suitable formulation may be used. A compendium of art-known formulations is found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Company, Easton, Pa. Reference to this manual is routine in the art.
- The dosages of the compounds of the invention will depend on a number of factors which will vary from patient to patient. However, it is believed that generally, the daily oral dosage will utilize 0.001-100 mg/kg total body weight, preferably from 0.01-50 mg/kg and more preferably about 0.01 mg/kg-10 mg/kg. The dose regimen will vary, however, depending on the conditions being treated and the judgment of the practitioner.
- It should be noted that the compounds of formula (1) can be administered as individual active ingredients, or as mixtures of several embodiments of this formula. In addition, the inhibitors of p38 kinase can be used as single therapeutic agents or in combination with other therapeutic agents. Drugs that could be usefully combined with these compounds include natural or synthetic corticosteroids, particularly prednisone and its derivatives, monoclonal antibodies targeting cells of the immune system, antibodies or soluble receptors or receptor fusion proteins targeting immune or non-immune cytokines, and small molecule inhibitors of cell division, protein synthesis, or mRNA transcription or translation, or inhibitors of immune cell differentiation or activation.
- As implied above, although the compounds of the invention may be used in humans, they are also available for veterinary use in treating animal subjects.
- The following examples are intended to illustrate but not to limit the invention. The compounds prepared below are inhibitors of p38.
-
-
- Synthesis of 2. To a solution of indole acid 1 (75 mg, 0.358 mMol) in DMF (1.5 mL) was added HATU (143 mg, 0.376 mMol) and triethylamine (92 mg, 0.716 mMol). After shaking occasionally for 15 min, this solution was added to (3R)-1-benzyl-3-(aminomethyl)pyrrolidine (82 mg, 0.430 mMol) and stirred overnight. The reaction was diluted with ethyl acetate and washed with water (×2) and brine. The organic layer was dried (Na2SO4), concentrated and chromatographed via radial chromatography (1:1 ETOAc:hexanes) to give 117 mg of a white solid.
- Step B
- Synthesis of Example 1 compound. A solution of Indole 2 (117 mg, 0.306 mMol) in DCM (4 mL) was cooled to 0° C. and a 2.0 M solution of oxalyl chloride (0.31 mL) in DCM was added dropwise via syringe. The reaction was stirred at 0° C. for one hour and then allowed to warm to room temperature for one hour. The solvent was removed under vacuum. The solvent was replaced by DCM (4 mL) cooled to 0° C. and a 2.0 M solution of dimethyl amine (0.62 mL) in DCM was added via syringe. After 0.5 h the solution was warmed to room temperature and stirred for an additional 30 minutes. The solvent was removed and the yellow residue re-suspended in DCM. The solution was washed with water, brine, dried (Na2SO4) and concentrated to give a yellow oil which was purified via radial chromatography (3:97 methanol:chloroform) to give 47 mg of a white solid.
-
- The above compound was prepared using the same procedure used in Example 1 using (3S)-1-benzyl-3-(aminomethyl)pyrrolidine in place of (3R)-1-benzyl-3-(aminomethyl)pyrrolidine.
-
- Triethylamine (7.88 g, 77.9 mMol) was added to a stirred solution of proline methyl ester (5.93 g, 35.4 mMol) in DCM (70 mL). The mixture was cooled to 0° C. and 4-fluorobenzoyl chloride (6.18 g, 39.0 mMol) was added slowly via syringe. The mixture was stirred for an additional 2 hr at 0° C. and allowed to warm to room temperature for an additional 2 h. The solution was then transferred to a separatory funnel, washed with 10% citric acid, 5% potassium carbonate, brine, dried (Na2SO4) and concentrated to give a thick oil. The residue was purified by flash chromatography to give 5.90 g of the product as a colorless oil.
Step B - Tetraethylenediamine (3.09 g, 26.6 mMol) was added to a solution of lithium diisopropyl amide (2.61 g, 24.4 mMol) in THF (25 mL) at −78° C. After the solution was allowed to stir for 15 min, a solution of 1-chloroacetonitrile (2.51 g, 33.3 mL) in THF (6 mL) was added dropwise via addition funnel. The reaction was stirred for an additional 1 h at −78° C., warmed to 0° C. and stirred for an additional 30 min. The reaction was then concentrated for form a dark oil, partitioned between DCM-water and the solid was removed by filtration. The organic layer was separated, washed with 2.0 M HCl, brine, dried (Na2SO4) and concentrated to give a dark oil. The residue was chromatographed using flash chromatography (30:70 EtOAc:hexanes) to give 3.34 g of the desired product as a thick colorless oil.
Step C - A solution of the nitrile (1.70 g, 5.82 mMol) was taken up in EtOH (50 mL). Using a 2 mL scoop, two scoops of Raney nickel in water was added. The reaction was placed on a Parr shaker at 45 PSI H2 for 5 days with additional scoops of Raney nickel added on day 2 and 3. After 5 days LCMS indicated near complete reduction of the nitrile to primary amine. The solution was filtered through celite and concentrated to give slightly yellow oil. The oil was taken up in toluene (25 mL) and refluxed for 48 hours. After removing the solvent, the resulting oil was chromatographed via radial chromatography to give 640 mg of the product as a white solid. Material was used without further purification.
Step D - A solution of lithium aluminum hydride (2.3 mL, 2.29 mMol) in ether was added to a solution of the diamide in THF (20 mL). The reaction was heated to reflux overnight. An additional 2.3 mL of lithium aluminum hydride solution was added and again the reaction was allowed to reflux overnight. At this point solid lithium aluminum hydride (174 mg, 2.58 mMol) was added and the reaction was refluxed for an addition 4 hours. The reaction was cooled to 0° C. and 0.35 mL water was added. When the bubbling died down 0.35 mL 15% sodium hydroxide was added followed by 1.05 mL water and 5 g Na2SO4. The mixture was stirred for 1 h, filtered through celite and the solvent was removed to give a yellow oil that contains the crude product which was used without further purification.
Step E - Synthesis of 2-{6-Chloro-5-[1-(4-fluoro-benzyl)-1,7-diaza-spiro[4.4]nonane-7-carbonyl]-1-methyl-1H-indol-3-yl}-N,N-dimethyl-2-oxo-acetamide was accomplished as described above for 6-Chloro-3-dimethylaminooxalyl-1-methyl-1H-indole-5-carboxylic acid (1-benzyl-pyrrolidin-3 S-ylmethyl)-amide using 1-(4-Fluoro-benzyl)-1,7-diaza-spiro[4.4]nonane in place of (3R)-1-benzyl-3-(aminomethyl)pyrrolidine.
-
- To a suspension of p-toluenesulfonamide (27.5 g, 1660 mMol) and anhydrous K2CO3 (45 g) in anhydrous acetonitrile (250 ml) was added 3-chloro-2-(chloromethyl)-1-propene (20 g, 160 mMol) in acetonitrile (25 mL) dropwise. The reaction mixture was refluxed for 4 h, and then concentrated. The residue was extracted with hot ethyl acetate (3×). The combined extracts were concentrated and the crude solid was re-crystallized from ethyl acetate to give 21 g (60%) of the title compound 1 as a colorless crystalline.
Step B - A slurry of N,N′-bis(p-toluenesulfonyl)-3,7-bis(methylene)-1,5-diazaacyclooctane (6.6 g, 9.9 mMol), LiAlH4 (5.7 g, 150 mMol) in THF (200 mL) was stirred under N2 for 2 days. The reaction mixture was quenched with 20% NaOH (15 mL) with external cooling and stirred continuously for 3 h. The precipitate was filtered off and washed with anhydrous ether. The combined extracts were concentrated to give 1.1 g of crude product containing some unidentified by-product. This product was used in the next reaction without further purification.
Step C - A mixture of the crude diamine (570 mg), 4-fluorobenzyl chloride (145 mg, 1 mMol) in EtOH was heated at reflux for 3 h. The reaction mixture was concentrated with Na2CO3 and extracted with EtOAc. The residue was purified by chromatography on silica gel eluting with 5% MeOH in CH2Cl2. (MeOH was increase to 100% gradually) to give 75 mg of the product as a white solid.
Step D - To a solution of indole (95 mg, 0.45 mMol) and amine 3 (75 mg, 0.3 mMol) in DMF was added HATU (172 mg, 0.45 mMol), followed by diisopropylethylamine (78 mg, 0.6 mMol). The reaction mixture was stirred at RT overnight, then concentrated. The residue was treated with Na2CO3, and extracted with EtOAc. The organic extracts was dried and concentrated. The residue was purified by chromatography on silica gel eluting with hexane:EtOAc (3:2) to give 50 mg (38%) of compound 6 as a white solid.
Step E - Oxalyl chloride (0.1 mL, 0.2 mMol) was added to a solution of indole in CH2Cl2 (5 mL) at 0° C. The reaction mixture was warmed to rt. slowly, stirred for 5 h, concentrated and then dried for 2 h. The residue was redissolved in CH2Cl2 and quenched with dimethylamine (0.2 mL, 0.4 mMol, 2 M in THF). The reaction mixture was treated with Na2CO3 and extracted with EtOAc. The combined extracts was dried and concentrated. The residue was purified on preparative TLC plate developed with 1% MeOH in EtOAc to give 2 mg of the desired product and 35 mg of the recovered starting material.
-
- To 4-fluorobenzaldehyde (2.48 g) in MeOH was added methylamine (40% aqueous solution, 2.0 mL). The reaction mixture was stirred at RT for 12 h at which time NaBH4 (0.38 g) was added. After stirring for 1 h the reaction was quenched with H2O and extracted with ethyl acetate. The combined extracts were dried, filtered, and concentrated to yield (4-fluorobenzyl)-methylamine (2.30 g) which was used without further purification.
Step B - (4-Fluoro-benzyl)-methyl-(2-nitro-cyclohexyl)-amine was prepared by dissolving (4-fluorobenzyl)-methylamine (139 mg) in CH2Cl2 (2.25 mL) and treating it with 1-nitro-1-cyclohexane (127 mg) at −78° C. and slowly warming it to RT. After the reaction was complete as monitored by HPLC, the reaction mixture was concentrated to yield the desired product which was immediately in the next step.
Step C - To crude (4-fluoro-benzyl)-methyl-(2-nitro-cyclohexyl)-amine (1.0 mMol) in (5:1) MeOH/H2O (30 mL) was added Raney-Nickel. The reaction mixture was placed under H2 (1 atm) and stirred for 16 h. The slurry was filtered through Celite and the volatiles removed in vacuo to yield N-(4-Fluoro-benzyl)-N-methyl-cyclohexane-1,2-diamine (20 mg).
Step D - 6-Chloro-3-dimethylaminooxalyl-1H-indole-5-carboxylic acid {2-[(4-fluoro-benzyl)-methyl-amino]-cyclohexyl}-amide was prepared as for Example 1.
-
- Isonipecotic acid (5.37 g, 44.2 mMol) was dissolved at −10° C. in CH2Cl2 under an atmosphere of argon. Et3N (6.53 ml, 46.4 mMol) was slowly added, followed by trifluoroacetic anhydride (6.62 ml, 46.4 mMol). The reaction mixture was stirred for 1 h at room temperature and then poured into H2O. The organic phase was separated and evaporated to dryness. The crude material thus obtained was dissolved in Et2O and extracted into a 10% NaHCO3 solution. Acidification to pH 4 with concentrated HCl and extraction with CH2Cl2 yielded, after evaporation, a white solid. (6.27 g, 27.85 mMol, 63% yield)
Step B -
- 1.69 g (7.52 mMol) of amide was treated with 10 ml thionyl chloride at 0° C. followed by heating the reaction mixture at reflux temperature overnight. At the end of reaction, excess thionyl chloride was removed under reduced pressure to give 1.83 g of the acid chloride. 1.37 g of 3-methoxy-acetanilide (8.3 mMol) in 20 ml of dry CH2Cl2 was then added to the above acid chloride, followed by slowly addition of 2.51 g (18.8 mMol) aluminum chloride at ambient temperature. The reaction mixture was heated to reflux for 12 h. It was then cooled and poured into a mixture of conc. HCl and ice. Product was extracted with EtOAc and the organic layer was washed with water, half saturated sodium bicarbonate solution and concentrated. Silica gel column separation (CH2Cl2) gave 0.42 g (1.13 mMol) of the product.
Step D - 0.417 g of N-{3-Methoxy-4-[1-(2,2,2-trifluoro-acetyl)-piperidine-4-carbonyl]-phenyl}-acetamide (1.12 mMol) was dissolved in 5 ml of dry DMF followed by addition of 0.12 g sodium periodate (0.56 mMol), 0.284 g iodine (1.12 mMol). Under argon protection, the reaction mixture was warmed up to 50° C. with an oil bath and continued for 24 hours. DMF was removed in vacuo, residue was taken up in EtOAc and washed with H2O, brine, dried over anhydrous sodium sulfate and concentrated. Silica gel column separation (20% EtOAc in Hexane) afforded 0.33 g of product.
Step E - To a dry and N2 filled 25 ml RB flask is added 0.5 g of N-{2-Iodo-5-methoxy-4-[1-(2,2,2-trifluoro-acetyl)-piperidine-4-carbonyl]-phenyl}-acetamide (1 mMol), 5 ml dry CH2Cl2, and 5 ml dry Et3N. At 0° C., 0.11 ml trimethylsilylacetylene (1.1 mMol) is added dropwise. At the end of addition, the reaction mixture is warmed up to room temperature and stirred for 2 h. Solvent is evaporated off, residue which is then dissolved in EtOAc filtered through Celite. The combined filtrate is washed with brine, dried over anhydrous sodium sulfate and concentrated. Silica gel column separation (40% EtOAc in Hexane) provide 0.42 g of product.
Step F - 0.42 g of N-{5-Methoxy-4-[1-(2,2,2-trifluoro-acetyl)-piperidine-4-carbonyl]-2-trimethylsilanyl-ethynyl-phenyl}-acetamide (0.9 mMol) is dissolved in 5 ml dry THF. Under nitrogen protection, 1.8 ml tetrabutylammnonium fluoride (1.8 mMol, 1M in THF) is added. The mixture is then heated under reflux temperature for 1 h. After THF is removed, residue is dried under vacuum, re-dissolved in EtOAc, washed with H2O, brine, dried over anhydrous sodium sulfate, and concentrated. Silical gel column separation (20% EtOAc in hexane) affords 0.22 g product.
Step G - Under nitrogen protection, 177 mg of 2,2,2-Trifluoro-1-[4-(6-methoxy-1H-indole-5-carbonyl)-piperidin-1-yl]-ethanone (0.5 mMol) is dissolved in 10 ml dry DMF. To this solution is added 22 mg of NaH (0.55 mMol, 60% dispersion in mineral oil) at 0° C. After stirring at 0° C. for about 10 min, the reaction mixture is warmed up to room temperature with continued stirring for 0.5 h. The reaction mixture is cooled back to 0° C., followed by addition of 0.034 mL of methyl iodide (0.55 mMol). The reaction is allowed to stir at 0° C. for 0.5 h before being warmed up to room temperature and with continued stirring at room temperature for 1 h. DMF is removed under reduced pressure, residue is taken up in CH2Cl2, washed with H2O, brine, dried over anhydrous sodium sulfate and concentrated. Silica gel column separation (CH2Cl2) affords 177 mg of product.
Step H - Under argon protection, 0.36 ml oxalyl chloride (0.72 mMol, 2M in CH2Cl2) is added into a 15-ml dry RB flask containing 177 mg of 2,2,2-Trifluoro-1-[4-(6-methoxy-1-methyl-1H-indole-5-carbonyl)-piperidin-1-yl]-ethanone (0.48 mMol) in 2 ml dry CH2Cl2 at 0° C. The reaction mixture is stirred at 0° C. for 10 min before being warmed up to room temperature and stirred at room temperature for 1 hour. Excess of oxalyl chloride is removed under vacuo and vacuum dried for 0.5 h. At 0° C., residue is dissolved in 2 ml dry CH2Cl2, followed by addition of 0.48 mL of dimethylamine (0.96 mMol, 2 M in THF). The reaction mixture is then stirred at 0° C. for 0.5 h before being warmed up to room temperature and stirring continued for 1 h. At the end of reaction, solvent is removed as well as unreacted dimethylamine residue. Residue is re-dissolved in CH2Cl2, washed with H2O, brine, dried over anhydrous sodium sulfate and concentrated. Silica gel column separation (2% MeOH in CHCl3) gave 204 mg of product.
Step I - To a 4 ml MeOH solution of 204 mg of 2-{6-Methoxy-1-methyl-5-[1-(2,2,2-trifluoro-acetyl)-piperidine-4-carbonyl]-1H-indol-3-yl}-N,N-dimethyl-2-oxo-acetamide (0.44° C.mMol) is added 123 mg of KOH (2.2 mMol) in 4 ml H2O. The reaction mixture is heated at reflux temperature for 1 h before being cooled down to room temperature. MeOH is removed in vacuo and 6 mL H2O is introduced to dilute the solution. Aqueous solution was then extracted with CH2Cl2 and organic layer is washed with brine, dried over anhydrous sodium sulfate and concentrated to give 145 mg of product.
Step J - 144 mg of 2-[6-Methoxy-1-methyl-5-(piperidine-4-carbonyl)-1H-indol-3-yl]-N,N-dimethyl-2-oxo-acetamide (0.39 mMol) is dissolved in 10 ml EtOH followed by the addition of 0.05 ml of 4-fluorobenzyl bromide (0.4 mMol). The reaction mixture is stirred at room temperature over night. After removing the solvent, residue is taken up in CH2Cl2 and washed with H2O, brine, dried over anhydrous sodium sulfate and concentrated. Silica gel column separation (2% MeOH in CH2Cl2) then gives 133 mg of product.
-
- Synthesis of 2: Methyl 4-amino-2-chlorobenzoate (1) (18.5 g) was dissolved in dichloromethane (350 ml) and methyl thioacetaldehyde dimethylacetal (13.6 g) was added. The mixture was cooled to −45° C. (dry ice/acetonitrile bath). N-chlorosuccinamide (16.0 g) in 350 ml dichloromethane was added dropwise over 1 hr 30 min while maintaining bath temp at −45° C. The reaction mixture was stirred additional 1 hr, then triethylamine (16 mL, 100 mMols) in 30 ml dichloromethane was added dropwise over 5 min, reaction was warmed to room temp, then refluxed for 16 h. Solvent was removed and residue taken up in 500 ml carbon tetrachloride, triethylamine-hydrochloric acid was removed by filtration, filtrate was heated to reflux for 2 h. Solvent was removed by rotary evaporation.
- The residue was dissolved in 250 ml tetrahydrofuran and 250 ml 10% hydrochloric acid was added. The mixture was stirred overnight at room temperature until the complete disappearance of the starting material was observed. Solvent was removed under vacuum, acidic aqueous solution was extracted with ethyl acetate (3×125 ml). The combined ethyl acetate extracts were washed with 10% hydrochloric acid, water and dried over anhydrous sodium sulfate. Solvent was removed under vacuum. Crude product mixture was purified on a silica column eluting with ethyl acetate:hexanes (15:85) to give 6.4 g of the desired product 2.
- Synthesis of 3: Methyl 6-Chloro-3-thiomethyl-5-indole carboxylate (5.2 g) was dissolved in 150 ml ethanol:tetrahydrofuran (9:3) and treated with Raney-Nickel. Reaction was monitored by mass spec at 30 min intervals, with subsequent addition of Raney-Nickel until reaction was complete. When reaction was complete reaction was carefully filtered through celite and the celite washed with methanol several times and filtrate evaporated. Residue was taken up in ethyl acetate, washed with water, dried over anhydrous sodium sulfate. The solvent was removed to give 3 (3.2 g).
- Synthesis of 4: Methyl ester 1.5 g was dissolved in 30 ml methanol/water 50:50. The reaction mixture was heated at 50° C. for 2 h with 4 Mol. equivalent sodium hydroxide. The reaction mixture was cooled in ice-bath, acidified to pH 3 with 5M hydrochloric acid. Removed methanol by rotary evaporation and extracted with ethyl acetate. The extract was washed with saturated sodium chloride and dried over anhydrous sodium sulfate. Evaporation of the solvent gave the desired acid 4 (1.48 g).
- Synthesis of 15: To a solution of aniline 1 (9.25 g, 0.05 mol) and pyruvic aldehyde dimethyl acetal 14 (11.8 g, 0.1 mol) in 200 mL glacial acetic acid was added anhydrous sodium sulfate (71.0 g, 0.5 mol) and the mixture was stirred for 30 min. Powdered sodium triacetoxy borohydride (31.8 g, 0.15 mol) was then added in portions for a period of 5 min. The reaction mixture was stirred for an additional 2 h. Acetic acid was removed under reduced pressure and the residue was made basic by adding sufficient amount of saturated sodium bicarbonate solution. The product was then extracted with ethyl acetate, dried with sodium sulfate and evaporated to get an oil. This was chromatographed on silica gel column using ethyl acetate:hexane (3:7) to give 15 (14 g) as colorless oil.
- Synthesis of 16 and 17: To a suspension of fresh aluminum chloride (18.5 g) in 200 ml dry chloroform at 0° C. was added a solution of ketal 15 (13.3 g) in 100 ml chloroform slowly and the mixture was allowed to warm up to the room temperature and stirred overnight. Ice-cold water was added carefully to quench the aluminum chloride and the organic layer was separated and washed with sodium bicarbonate solution, dried and evaporated to get a white solid. The isomers were separated using silica gel column chromatography using ethyl acetate:hexane (1:9). The 6-cholo indole 17 (2.0 g) eluted first followed by 4-chloro isomer 16 (3.8 g).
- Synthesis of 18. To a solution of 1.3 g of indole 17 in 15 mL of methanol was added a solution of 0.9 g of sodium hydroxide in 20 mL of water. The reaction mixture was heated at 50° C. for 4 h where upon a clear solution resulted. Cooled and evaporated off methanol and the residue was diluted with water and acidified with 10% hydrochloric acid. The product was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and evaporated to obtain indole acid 18 (1.2 g) as white solid.
-
- Synthesis of 21: To a solution of methyl 4-amino-6-methoxy 5-benzoate (19) (6.0 g, 0.033 mol) and dimethyl acetal 20 (7.0 g, 0.066 mol) in 150 mL glacial acetic acid was added anhydrous sodium sulfate (47.0 g, 0.33 mol) and the mixture was stirred for 30 min. Powdered sodium triacetoxy borohydride (20.1 g, 0.099 mol) was then added in portions for a period of 5 min. The reaction mixture was stirred for an additional 2 h. Acetic acid was removed under reduced pressure and the residue was made basic by adding sufficient amount of saturated sodium bicarbonate solution. The product was then extracted with ethyl acetate, washed with saturated sodium chloride, dried over sodium sulfate and evaporated to get an oil. This was chromatographed on silica gel column using ethyl acetate:hexane (3:7) as eluent and the desired product 21 was obtained (5.2 g) as an oil.
- Synthesis of 22: To a solution of 21 (3.6 g) and iodomethane (5.7 g) in 50 mL anhydrous dimethylformamide was added potassium t-butoxide (1.0 M in tetrahydrofuran, 20 mL) at ambient temperature. The reaction mixture was stirred at ambient temperature for 0.5 h and poured into 250 mL ethyl acetate, washed with water (4×100 mL), brine (50 mL) and dried over magnesium sulfate. Evaporation of solvent afforded 3.26 g of 22. The product was used for next step without purification.
- Synthesis of 23: To a suspension of anhydrous aluminum chloride (0.71 g) in 20 mL anhydrous 1,2-dichloroethane was added, dropwise a solution of 22 (1 g) in 10 mL 1,2-dichloroethane with stirring. The reaction was heated to 80° C. for 0.5 h. At the end of this time, the reaction mixture was quenched with methanol, solvents evaporated, then ethyl acetate (100 mL) was added. The organic phase was washed with water, aq. sodium bicarbonate and brine and concentrated. The crude product was purified by silica chromatography using ethyl acetate:hexane (3:7) to give 23 0.22 g.
Claims (36)
1. A compound of the formula:
and the pharmaceutically acceptable salts thereof wherein:
Ar is an aryl group substituted with 0-5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and wherein two of said optional substituents on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members;
X is an aliphatic monocyclic or aliphatic polycyclic moiety optionally comprising one or more hetero ring atoms wherein the cyclic moiety may be optionally substituted with one or more noninterfering substituents and where said optional substituents may constitute a ring fused to X;
L1 is CO, SO2, alkylene (1-4C), or CH2NHCO;
L2 is alkylene (1-4C) or alkenylene (2-4C) optionally substituted with one or two moieties selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, alkyl-OOCR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, and R3Si, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and wherein two substituents on L2 can be joined to form a non-aromatic saturated or unsaturated ring that includes 0-3 heteroatoms which are O, S and/or N and which contains 3 to 8 members or said two substituents can be joined to form a carbonyl moiety or an oxime, oximeether, oximeester or ketal of said carbonyl moiety;
with the proviso that —X— is not:
wherein Za is CR or N wherein R is hydrogen or a noninterfering substituent; each Ra is independently a noninterfering substituent; and each of 1 and k is 0-3; and m is 0-4;
n is 0-3;
each R1 is independently halo, alkyl, OCOR, OR, NRCOR, SR, or NR2, wherein R is hydrogen, alkyl or aryl or heteroforms thereof;
represents a single or double bond;
one Z2 is CA or CR2A; the other Z2 is CR3, CR3 2, NR4 or N; and each R2, R3 and R4 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, heteroaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and two of R2 and/or R3 on adjacent positions can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members, or an oxime, oximeether, oximeester or ketal thereof;
Z3 is NR5 or O; where R5 is H or is optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylaryl, or is SOR, SO2R, RCO, COOR, alkyl-COR, SO3R, CONR2, SO2NR2, CN, CF3, NR2, OR, alkyl-SR, alkyl-SOR, alkyl-SO2R, alkyl-OCOR, alkyl-COOR, alkyl-CN, alkyl-CONR2, or R3Si, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof;
A is -Wi-COXjY, where Y is selected from COR6, tetrazole, 1,2,3-triazole, 1,2,4-triazole, and imidazole, each of W and X is substituted or unsubstituted alkylene or alkenylene, each of 2-6 Å; each of i and j is independently 0 or 1; and R6 is H, or is straight or branched chain alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, or heteroarylalkyl, each optionally substituted with halo, alkyl, SR, SOR, SO2R, SO2NR2, OR, NR2, OCOR, NRCOR, NRCONR2, NRSO2R, NRSO2NR2, OCONR2, CN, COOR, CONR2, COR, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof, or
wherein R6 is OR, NR2, SR, NRCONR2, OCONR2, or NRSO2NR2, wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof and wherein two R attached to the same atom may form a 3-8 member carbocyclic or heterocyclic ring and wherein said ring may further be substituted by alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, each optionally substituted with halo, SR, OR, NR2, OCOR, NRCOR, NRCONR2, NRSO2R, NRSO2NR2, OCONR2, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl or heteroforms thereof wherein two R attached to the same atom may form a 3-8 member ring, optionally substituted as above defined.
2. The compound of claim 1 wherein Y is COR6.
3. The compound of claim 2 wherein Y is tetrazole; 1,2,3-triazole; 1,2,4-triazole; or imidazole.
4. The compound of claim 1 wherein each of i and j is 0.
5. The compound of claim 1 wherein j is 0.
6. The compound of claim 1 wherein Z3 is NR5.
7. The compound of claim 1 wherein R5 is H, or is optionally substituted alkyl or acyl.
8. The compound of claim 1 wherein R2 and R3 are independently selected from halo, OR and alkyl.
9. The compound of claim 1 wherein L1 is CH2 or CO and L2 is CH2 or CHOH.
10. The compound of claim 9 wherein L1 is CO.
11. The compound of claim 1 wherein L2 and/or L1 is unsubstituted alkylene.
12. The compound of claim 1 wherein L2 and/or L1 is unsubstituted methylene, or methylene substituted with alkyl.
13. The compound of claim 1 wherein Ar is optionally substituted phenyl.
14. The compound of claim 13 wherein said optional substitution is by halo, OR, or alkyl.
15. The compound of claim 14 wherein said phenyl is unsubstituted or has a single substituent.
16. The compound of claim 1 wherein R1 is halo or alkoxy.
17. The compound of claim 16 wherein n is 0, 1 or 2.
18. The compound of claim 1 wherein L1 is coupled to the α ring at the 4-, 5- or 6-position.
19. The compound of claim 1 wherein Z2 at position 3 is CA or CHA.
20. The compound of claim 19 wherein the Z2 at position 2 is CR3 or CR3 2.
21. The compound of claim 20 wherein R3 is hydrogen, or is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, NH-aroyl, halo, OR, NR2, SR, SOR, SO2R, OCOR, NRCOR, NRCONR2, NRCOOR, OCONR2, RCO, COOR, SO3R, CONR2, SO2NR2, NRSO2NR2, CN, CF3, R3Si, and NO2, wherein each R is independently H, alkyl, alkenyl or aryl and two of R1 can be joined to form a fused, optionally substituted aromatic or nonaromatic, saturated or unsaturated ring which contains 3-8 members.
22. The compound of claim 21 wherein each R3 is selected from the group consisting of H, alkyl, acyl, aryl, arylalkyl, heteroaryl, halo, OR, NR2, SR, NRCOR, RCO, COOR, and CN, wherein each R is independently H, alkyl or aryl.
23. The compound of claim 19 wherein Z2 at position 2 is N or NR4.
24. The compound of claim 23 wherein R4 is H, or alkyl, alkenyl, alkynyl, aryl, arylalkyl, acyl, aroyl, heteroaryl, or is SOR, SO2R, RCO, COOR, alkyl-COR, SO3R, CONR2, SO2NR2, CN, CF3, or R3Si wherein each R is independently H, alkyl, alkenyl or aryl.
26. The compound of claim 1 wherein the portion of the compound represented by L2-X-L1 is selected from the group consisting of:
wherein, in each of structures (I) to (IV):
one or more of the ring carbon atoms not bound to L2 or L1 may be optionally replaced with NR4, where R4 is as defined in claim 1; or is represented by CR2 2, where R2 is as defined in claim 1 but at least one R2 is other than H; and/or
one or both of the ring carbon atoms bound to L2 and L1 may be independently replaced by CR2 where R2 is as defined in claim 1 , but is other than H; and/or
one or both of the ring carbon atoms bound to L2 and L1 may be replaced by N.
27. The compound of claim 26 wherein R2 and R3 are independently selected from halo, OR and alkyl.
28. The compound of claim 26 wherein L2-X-L1 is structure II and n and p are both 1, or n and p are both 2, or one of n and p is 1 and the other is 2.
29. The compound of claim 26 wherein L2-X-L1 is structure (IV) and n and p are both 2.
30. The compound of claim 26 wherein the ring carbon bonded to L1 is replaced with N; or the ring carbon bonded to L2 is replaced with N; or both of said ring carbons are replaced with N.
31. The compound of claim 26 wherein the ring carbon bonded to L2 is replaced with nitrogen and the ring atom bonded to L1 is carbon.
32. The compound of claim 26 wherein L2 is methylene and -L1- is —CH2—NH—CO— such that the portion of the compound represented by L2-X-L1- consists of CH2—X—CH2—NH—CO—.
35. A pharmaceutical composition which composition comprises a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient.
36. A method to treat rheumatoid arthritis, which comprises administering to a subject in need of such treatment a compound of claim 1 or a pharmaceutical composition thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/098,905 US20050171183A1 (en) | 2000-11-20 | 2005-04-04 | Indole-type inhibitors of p38 kinase |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25216300P | 2000-11-20 | 2000-11-20 | |
US09/989,991 US6890938B2 (en) | 2000-11-20 | 2001-11-20 | Indole-type inhibitors of p38 kinase |
US11/098,905 US20050171183A1 (en) | 2000-11-20 | 2005-04-04 | Indole-type inhibitors of p38 kinase |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/989,991 Continuation US6890938B2 (en) | 2000-11-20 | 2001-11-20 | Indole-type inhibitors of p38 kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050171183A1 true US20050171183A1 (en) | 2005-08-04 |
Family
ID=22954860
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/989,991 Expired - Fee Related US6890938B2 (en) | 2000-11-20 | 2001-11-20 | Indole-type inhibitors of p38 kinase |
US11/098,905 Abandoned US20050171183A1 (en) | 2000-11-20 | 2005-04-04 | Indole-type inhibitors of p38 kinase |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/989,991 Expired - Fee Related US6890938B2 (en) | 2000-11-20 | 2001-11-20 | Indole-type inhibitors of p38 kinase |
Country Status (6)
Country | Link |
---|---|
US (2) | US6890938B2 (en) |
EP (1) | EP1339708A2 (en) |
JP (1) | JP2004536779A (en) |
AU (1) | AU2002237657A1 (en) |
CA (1) | CA2429382A1 (en) |
WO (1) | WO2002044168A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867209B1 (en) * | 1998-05-22 | 2005-03-15 | Scios, Inc. | Indole-type derivatives as inhibitors of p38 kinase |
IL146309A (en) * | 1999-05-21 | 2008-03-20 | Scios Inc | INDOLE-TYPE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS INHIBITORS OF p38 KINASE |
SE0100326D0 (en) * | 2001-02-02 | 2001-02-02 | Astrazeneca Ab | New compounds |
JP2006506346A (en) * | 2002-09-03 | 2006-02-23 | サイオス インク. | Indole derivatives as p38 kinase inhibitors |
WO2004032874A2 (en) * | 2002-10-09 | 2004-04-22 | Scios Inc. | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE |
WO2004037818A1 (en) | 2002-10-24 | 2004-05-06 | Glaxo Group Limited | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
DE102004010132A1 (en) * | 2004-02-27 | 2005-09-15 | Merck Patent Gmbh | piperidine |
US20070066833A1 (en) * | 2005-08-19 | 2007-03-22 | Scios, Inc. | Methods to synthesize indoles as precursors for pharmaceuticals |
JP2007217322A (en) * | 2006-02-15 | 2007-08-30 | Ube Ind Ltd | Pharmaceutical composition for treatment or prophylaxis of chronic obstructive pulmonary disease |
CA2648055A1 (en) * | 2006-04-05 | 2007-10-18 | Wyeth | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands |
WO2008079105A1 (en) * | 2006-08-22 | 2008-07-03 | Scios Inc. | Methods to synthesize indoles as precursors for pharmaceuticals |
WO2012078674A1 (en) | 2010-12-06 | 2012-06-14 | Confluence Life Sciences, Inc. | Substituted indole/indazole-pyrimidinyl compounds |
WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166136A (en) * | 1988-07-25 | 1992-11-24 | Glaxo Group Limited | Spirolactam containing peptides |
US20020160388A1 (en) * | 2000-11-20 | 2002-10-31 | Roberto Macina | Compositions and methods relating to lung specific genes and proteins |
US20030109682A1 (en) * | 2001-09-07 | 2003-06-12 | Daniel Santi | Maytansines and maytansine conjugates |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69533874T2 (en) | 1994-08-01 | 2005-12-29 | Safety Equipment Sweden Ab | VENTILATOR |
US5658903A (en) * | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
USH2007H1 (en) | 1996-01-19 | 2001-12-04 | Fmc Corporation | Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines |
EP0922042A1 (en) * | 1996-08-09 | 1999-06-16 | Smithkline Beecham Corporation | Novel piperazine containing compounds |
WO1998007425A1 (en) | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
ATE316961T1 (en) | 1998-05-22 | 2006-02-15 | Scios Inc | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF HEART FAILURE AND OTHER DISEASES |
JP2002523448A (en) | 1998-08-28 | 2002-07-30 | サイオス インコーポレイテッド | Inhibitors of p38-α kinase |
CN1310906C (en) | 1999-05-21 | 2007-04-18 | 肖斯公司 | Indole-type derivatives as inhibitors of p38 kinase |
AU2001241927A1 (en) * | 2000-02-28 | 2001-09-12 | Scios Inc. | Inhibitors of p38-alpha kinase |
-
2001
- 2001-11-20 EP EP01986461A patent/EP1339708A2/en not_active Ceased
- 2001-11-20 JP JP2002546538A patent/JP2004536779A/en active Pending
- 2001-11-20 US US09/989,991 patent/US6890938B2/en not_active Expired - Fee Related
- 2001-11-20 AU AU2002237657A patent/AU2002237657A1/en not_active Abandoned
- 2001-11-20 WO PCT/US2001/043439 patent/WO2002044168A2/en active Application Filing
- 2001-11-20 CA CA002429382A patent/CA2429382A1/en not_active Abandoned
-
2005
- 2005-04-04 US US11/098,905 patent/US20050171183A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166136A (en) * | 1988-07-25 | 1992-11-24 | Glaxo Group Limited | Spirolactam containing peptides |
US20020160388A1 (en) * | 2000-11-20 | 2002-10-31 | Roberto Macina | Compositions and methods relating to lung specific genes and proteins |
US20030109682A1 (en) * | 2001-09-07 | 2003-06-12 | Daniel Santi | Maytansines and maytansine conjugates |
Also Published As
Publication number | Publication date |
---|---|
WO2002044168A2 (en) | 2002-06-06 |
JP2004536779A (en) | 2004-12-09 |
US6890938B2 (en) | 2005-05-10 |
AU2002237657A1 (en) | 2002-06-11 |
CA2429382A1 (en) | 2002-06-06 |
WO2002044168A3 (en) | 2003-05-22 |
US20030100588A1 (en) | 2003-05-29 |
EP1339708A2 (en) | 2003-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050171183A1 (en) | Indole-type inhibitors of p38 kinase | |
US6867209B1 (en) | Indole-type derivatives as inhibitors of p38 kinase | |
US7214679B2 (en) | Piperidine/piperazine-type inhibitors of p38 kinase | |
EP1178983B1 (en) | Indole-type derivatives as inhibitors of p38 kinase | |
US6821966B2 (en) | Inhibitors of p38 kinase | |
US7393851B2 (en) | Azaindole derivatives as inhibitors of p38 kinase | |
US20070161649A1 (en) | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | |
US7488744B2 (en) | Indole-type derivatives as inhibitors of p38 kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |